<SEC-DOCUMENT>0001193125-16-794607.txt : 20161215
<SEC-HEADER>0001193125-16-794607.hdr.sgml : 20161215
<ACCEPTANCE-DATETIME>20161215171903
ACCESSION NUMBER:		0001193125-16-794607
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20161214
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161215
DATE AS OF CHANGE:		20161215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPLIGEN CORP
		CENTRAL INDEX KEY:			0000730272
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				042729386
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14656
		FILM NUMBER:		162054459

	BUSINESS ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		7814499560

	MAIL ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d312959d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): December&nbsp;14, 2016 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>REPLIGEN CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-14656</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>04-2729386</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(781) 250-0111 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;1.01. Entry into a Material Definitive Agreement. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2016, Repligen Corporation (the &#147;Company&#148;) entered into a Stock Purchase Agreement (the &#147;Purchase Agreement&#148;) with
Novasep Process SAS, a French corporation (&#147;Novasep&#148;), and John Connors (together with Novasep, the &#147;Sellers&#148;), pursuant to which the Company acquired TangenX Technology Corporation, a Massachusetts corporation
(&#147;TangenX&#148;), through the purchase of (i)&nbsp;20.29% of the outstanding equity of TangenX from John Connors and (ii)&nbsp;100% of the equity of TangenX Holding, Inc., a Delaware corporation (&#147;TangenX Holding&#148;) holding 79.71% of
the outstanding equity of TangenX, from Novasep (such transaction, the &#147;Acquisition&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company completed the Acquisition on
December&nbsp;14, 2016 (the &#147;Closing Date&#148;), for a total purchase price in cash of &#128;35.6&nbsp;million plus the assumption of a &#128;1.0&nbsp;million tax liability and a &#128;0.4&nbsp;million working capital deficit (the
&#147;Closing Consideration&#148;). The Company funded the Closing Consideration with cash on-hand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement contains customary
representations and warranties and covenants by each party. The Purchase Agreement also provides that each Seller will indemnify the Company for breaches of the warranties and covenants of such Seller, as well as certain other specified matters,
subject to certain limitations set forth therein, including, among other things, limitations on the period during which the Company may make certain claims for indemnification and limitations on the amounts and taxes for which each of the Sellers
may be liable. A portion of the Closing Consideration was contributed to a third-party escrow fund against which the Company may make indemnification claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement also contains non-competition and non-solicitation clauses under which the Seller Parties must not, for two years following the
consummation of the Acquisition, (i)&nbsp;engage in any business competitive with the business of TangenX, (ii)&nbsp;solicit any customer, supplier, agent or distributor of TangenX, or (iii)&nbsp;solicit any employee of TangenX hired by the Company
for a period of one year following their employment with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither the Company nor any of its affiliates nor any person who is a director or
officer of the Company had a material relationship with the Sellers, TangenX, TangenX Holding or any of their respective affiliates prior to the completion of the Acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement contains warranties and covenants that the Company, on one hand, and John Connors and Novasep, on the other hand, made to each other as
of specific dates. The assertions embodied in those warranties and covenants were made solely for purposes of the Purchase Agreement between the parties and may be subject to important qualifications and limitations agreed to by the parties in
connection with negotiating its terms, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of the Purchase Agreement. Moreover, the warranties may be subject to a contractual standard
of materiality that may be different from what may be viewed as material to investors or securityholders, or may have been used for the purpose of allocating risk between the parties to the Purchase Agreement rather than establishing matters as
facts. Moreover, information concerning the subject matter of the warranties may change after the date of the Purchase Agreement, which subsequent information may or may not be fully reflected in the Company&#146;s public disclosures. For the
foregoing reasons, no person should rely on the warranties as statements of factual information at the time they were made or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing
description of the Acquisition and the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, a copy of which is filed herewith and incorporated herein by
reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2.01. Completion of Acquisition or Disposition of Assets. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Purchase Agreement described in Item&nbsp;1.01 of this Current Report on Form 8-K, on the Closing Date, the Company completed the Acquisition
and acquired TangenX through the purchase of all of the equity of </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
TangenX held by John Connors and all of the equity of TangenX Holding held by Novasep. As consideration for the Acquisition and the other transactions contemplated by the Purchase Agreement, the
Company paid the Closing Consideration to the Sellers on the Closing Date. The full text of Item&nbsp;1.01 and the full text of the Purchase Agreement are incorporated into this Item&nbsp;2.01. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01 Regulation FD Disclosure. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
December&nbsp;15, 2016, the Company issued a press release announcing the Acquisition. This press release is attached to this Current Report on Form 8-K and furnished as Exhibit 99.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item&nbsp;7.01 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed &#147;filed&#148; for purposes of
Section&nbsp;18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall any of it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"><I>Financial statements of business acquired.</I> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company intends to file the financial statements
relating to the Acquisition described in Item&nbsp;2.01 above under cover of Form 8-K/A with the Commission no later than 71 calendar days after the date this Current Report on Form 8-K was required to be filed. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"><I>Pro forma financial information.</I> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company intends to furnish pro forma financial information
relating to the Acquisition described in Item&nbsp;2.01 above under cover of Form 8-K/A with the Commission no later than 71 calendar days after the date this Current Report on Form 8-K was required to be filed. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"><I>Exhibits.</I> </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stock Purchase Agreement, dated December 14, 2016, by and among Repligen Corporation, Novasep Process SAS and John Connors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release by Repligen Corporation, dated December 15, 2016.</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Schedules, exhibits, and similar supporting attachments or agreements to the Stock Purchase Agreement are omitted pursuant to Item 601(b)(2) of Regulation S-K. Repligen Corporation agrees to furnish a supplemental copy
of any omitted schedule or similar attachment to the Securities and Exchange Commission upon request. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">REPLIGEN CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Dated: December&nbsp;15, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Tony J. Hunt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tony J. Hunt</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive
Officer</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stock Purchase Agreement, dated December 14, 2016, by and among Repligen Corporation, Novasep Process SAS and John Connors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release by Repligen Corporation, dated December 15, 2016.</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Schedules, exhibits, and similar supporting attachments or agreements to the Stock Purchase Agreement are omitted pursuant to Item 601(b)(2) of Regulation S-K. Repligen Corporation agrees to furnish a supplemental copy
of any omitted schedule or similar attachment to the Securities and Exchange Commission upon request. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>d312959dex21.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 2.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>By and Among </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOVASEP
PROCESS SAS AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JOHN CONNORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(collectively, the &#147;Sellers&#148;) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>And </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPLIGEN
CORPORATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(&#147;Purchaser&#148;) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DATE:&nbsp;DECEMBER 14, 2016 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TABLE OF CONTENTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 1 DEFINITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 2 PURCHASE OF STOCK; PURCHASE PRICE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 3 REPRESENTATIONS AND WARRANTIES OF THE SELLERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF THE PURCHASER</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 5 COVENANTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 6 INDEMNIFICATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 7 MISCELLANEOUS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">APPENDIX&nbsp;A:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DEFINITIONS</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">APPENDIX&nbsp;B:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">STOCK OWNERSHIP OF TANGENX AND TANGENX HOLDING</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">APPENDIX&nbsp;C:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ALLOCATION OF PURCHASE PRICE AMONG THE SELLERS</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">APPENDIX&nbsp;D:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">APPENDIX&nbsp;E:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PRESS RELEASE</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">APPENDIX&nbsp;F:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ESCROW AGREEMENT</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">APPENDIX&nbsp;G:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ESTIMATED WORKING CAPITAL STATEMENT</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">APPENDIX&nbsp;H:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EXCEPTIONS TO THE TANGENX ACCOUNTING PRACTICES</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">APPENDIX&nbsp;I:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CALCULATION OF ESTIMATED TAX ADJUSTMENT AMOUNT</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">APPENDIX&nbsp;J:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EMPLOYMENT AGREEMENT FOR JOHN CONNORS</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS STOCK PURCHASE AGREEMENT</B> (this &#147;<B>Agreement</B>&#148;) is made and entered into as of the 14th day of December, 2016, by and
among NOVASEP PROCESS SAS, a French corporation (&#147;<B>Novasep</B>&#148;), and JOHN CONNORS (&#147;<B>Connors</B>&#148;) (each, a &#147;<B>Seller</B>&#148;, and collectively, the &#147;<B>Sellers</B>&#148;), and REPLIGEN CORPORATION, a Delaware
corporation (the &#147;<B>Purchaser</B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RECITALS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;The Sellers have consummated a restructuring transaction, pursuant to which:&nbsp;(i)&nbsp;Novasep formed TangenX
Holding, Inc. (&#147;<B>TangenX Holding</B>&#148;), a Delaware corporation, on November 10, 2016, and thereafter contributed one-hundred percent (100%) of its shares of capital stock of Novasep, Inc. to TangenX Holding (the
&#147;<B>Contribution</B>&#148;); (ii) immediately following the Contribution, and as part of an integrated plan, Novasep, Inc. was converted from a New Jersey corporation to a New Jersey limited liability company and is now known as Novasep, LLC
(the &#147;<B>Conversion</B>&#148;) (the Contribution and the Conversion are intended to qualify as a tax-free reorganization under Code Section 368(a)(1)(F)); (iii) following the Conversion, Novasep, LLC distributed one-hundred percent (100%) of
its stock in TangenX Technology Corporation, a Massachusetts corporation (&#147;<B>TangenX</B>&#148;), to TangenX Holding; (iv) Groupe Novasep SAS formed Novasep Americas, Inc. (&#147;<B>Novasep Americas</B>&#148;) as a newly-formed Delaware
corporation and a wholly-owned subsidiary of Groupe Novasep SAS, on October 20, 2016; and (v) Novasep Americas purchased one-hundred percent (100%) of the equity interests of Novasep, LLC from TangenX Holding and TangenX Holding distributed the cash
purchase price to Novasep (collectively, the &#147;<B>Reorganization</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;On October 26, 2016, TangenX
repurchased (the &#147;<B>Repurchase</B>&#148;) all of the shares of common stock of TangenX then held by Mark Perreault (the &#147;<B>Repurchased Stock</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C.&nbsp;&nbsp;&nbsp;&nbsp;Following the Reorganization and the Repurchase, (i) Novasep owns 100% of the equity of TangenX Holding, and (ii)
TangenX Holding owns 79.71% of the equity of TangenX, and Connors owns 20.29% of the equity of TangenX. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D.&nbsp;&nbsp;&nbsp;&nbsp;Purchaser desires to purchase (i) 100% of the equity of TangenX Holding owned by Novasep, and (ii) 100% of the
equity of TangenX owned by Connors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E.&nbsp;&nbsp;&nbsp;&nbsp;Upon consummation of these transactions, the Purchaser will own directly
(following the Purchaser&#146;s purchase hereunder from Connors) and indirectly (through TangenX Holding) one hundred percent (100%) of the issued and outstanding equity of TangenX. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AGREEMENT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
consideration of the foregoing Recitals and the mutual promises contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Purchaser and the Sellers agree as follows:
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes
of this Agreement, all capitalized terms not otherwise defined herein shall have the meanings ascribed to them in <B><U>Appendix A</U></B> attached hereto. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURCHASE OF
STOCK; PURCHASE PRICE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1&nbsp;&nbsp;&nbsp;&nbsp;Purchase and Sale of Stock. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Novasep represents to the Purchaser that the current stock ownership of TangenX Holding is as
described in <U>Section 3.2(a)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Novasep represents to the Purchaser that its current stock
ownership of TangenX is as described in <U>Section 3.2(b)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Connors represents to the
Purchaser that his current stock ownership of TangenX is as described in <U>Section 3.2(b)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Novasep hereby sells to the Purchaser all of the stock of TangenX Holding owned by Novasep and which
is listed on <B><U>Appendix B</U></B> (the &#147;<B>Novasep-Owned Stock</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Connors
hereby sells to the Purchaser all of the Class A voting and Class B nonvoting common stock of TangenX owned by Connors and which is listed on <B><U>Appendix B</U></B> (the &#147;<B>Connors-Owned Stock</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;The Novasep-Owned Stock and the Connors-Owned Stock shall be collectively referred to hereafter as
the &#147;<B>Stock</B>&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;In reliance upon the representations, warranties and covenants
contained in this Agreement, the Purchaser agrees to purchase the Stock from the Sellers, and the Sellers agree to sell, transfer, convey, assign and deliver the Stock to the Purchaser on the terms and conditions set forth in this Agreement. Such
sale, transfer, conveyance, assignment and delivery of the Stock shall convey good and valid title to the Stock, free and clear of any and all Rights and Encumbrances, and at such time the Stock will be fully paid and non-assessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Purchase Price. </B>The term &#147;<B>Purchase Price</B>&#148; means an amount equal to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the Closing Cash Consideration; plus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;the Escrow Amount (to the extent released to the
Sellers in accordance with the terms set forth herein and the Escrow Agreement); plus </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;if the
Closing Cash Adjustment is positive, the absolute amount of the Closing Cash Adjustment; minus </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;if the Closing Cash Adjustment is negative, the absolute amount of the Closing Cash Adjustment;
minus </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;the Tax Adjustment Amount (as defined in Section 5.3(h)) as calculated as of the Closing
Date (the &#147;<B>Estimated Tax Adjustment Amount</B>&#148;).&nbsp;The calculation of the Estimated Tax Adjustment Amount is set forth on <B><U>Appendix I</U></B>.&nbsp;The Tax Adjustment Amount shall be deducted from the consideration paid by the
Purchaser to Novasep in accordance with <B><U>Appendix C</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Payment of Purchase Price. </B>On
the Closing Date, the Purchaser shall, by wire transfer of immediately available funds, (i) pay to each Seller such consideration as set forth on <B><U>Appendix C</U></B> in accordance with the wire instructions provided to the Purchaser by such
Seller prior to the Closing (the &#147;<B>Wire Transfer Instructions</B>&#148;), and (ii) deposit cash in the amount of the Escrow Amount to the Escrow Account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Pre-Closing Estimates. </B>Attached hereto as <B><U>Appendix G</U></B> is Sellers&#146; good faith
estimate of each of the following information (the &#147;<B>Estimated Working Capital Statement</B>&#148;):&nbsp;(a) the balance sheet of TangenX as of the close of business on the Closing Date, without giving effect to the transactions contemplated
by this Agreement and prepared in accordance with the TangenX Accounting Practices; (b) the Working Capital Amount (the &#147;<B>Estimated Working Capital</B>&#148;); (c) the Cash and Cash Equivalents (the &#147;<B>Estimated </B><B>Cash and Cash
Equivalents</B>&#148;); (d) the Indebtedness of TangenX as of immediately prior to the Closing (the &#147;<B>Estimated Indebtedness</B>&#148;); (e) the unpaid Transaction Costs as of immediately prior to the Closing (the &#147;<B>Estimated
Transaction Costs</B>&#148;); and (f) a calculation of the Closing Cash Consideration and the Closing Cash Adjustment; in each case, along with reasonable supporting detail to evidence the calculation of such amount.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5&nbsp;&nbsp;&nbsp;&nbsp;Post-Closing Purchase Price Adjustments. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Within ninety (90)&nbsp;days after the Closing Date, the Purchaser shall prepare and deliver to the
Sellers the Initial Working Capital Statement, which shall include reasonable detail supporting the Purchaser&#146;s calculations set forth therein and reasonable detail supporting any change from the amounts set forth in the Estimated Working
Capital Statement or the calculations set forth therein.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Subject to complying with the
restrictions set forth in <U>Section 5.1</U>, at reasonable times during normal business hours during the 30-day period immediately following the Sellers&#146; receipt of the Initial Working Capital Statement, each Seller and his or its
Representatives shall be permitted to review the records of TangenX relating to the Initial Working Capital Statement that are reasonably requested by such Seller, and the Purchaser shall make reasonably available to each Seller and his or its
Representatives the individuals employed by TangenX and/or the Purchaser that were </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
responsible for the preparation of the Initial Working Capital Statement in order to respond to the reasonable inquiries of such Seller related thereto. Any information provided to the Sellers
pursuant to this <U>Section 2.5</U> shall be considered Covered Information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The Sellers shall
deliver to the Purchaser by the Objection Deadline Date either a notice indicating that the Sellers accept the Initial Working Capital Statement (&#147;<B>Notice of Acceptance</B>&#148;) or a detailed statement describing the Sellers&#146;
objections to the Initial Working Capital Statement (&#147;<B>Notice of Disagreement</B>&#148;); <U>provided</U>, that any objections must be on the basis that the amounts set forth in the Initial Working Capital Statement (i)&nbsp;were not
determined in accordance with the TangenX Accounting Practices (or in the case of Indebtedness of the types included in clauses (d), (f) and (h) of the definition of Indebtedness, GAAP) or otherwise not calculated in accordance with the applicable
terms of this Agreement, or (ii)&nbsp;were arrived at based on mathematical or clerical error. If the Sellers deliver to the Purchaser a Notice of Acceptance, or the Sellers do not deliver a Notice of Disagreement on or before the Objection Deadline
Date, then, effective as of the earlier of the date of delivery of such Notice of Acceptance and the end of the Objection Deadline Date, the Initial Working Capital Statement shall be deemed to be the Final Working Capital Statement. If the Sellers
timely deliver a Notice of Disagreement, only those matters specified in such Notice of Disagreement shall be deemed to be in dispute (the &#147;<B>Disputed Items</B>&#148;), and all other matters included in the Initial Working Capital Statement
shall be final, binding and conclusive upon the parties hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The Disputed Items set forth on
the Notice of Disagreement shall be resolved as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Sellers and the Purchaser shall
first use commercially reasonable efforts to resolve such Disputed Items. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Any resolution by
the Sellers and the Purchaser as to such Disputed Items shall be final and binding on the parties hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;If the Sellers and the Purchaser do not reach a resolution of all Disputed Items set forth on the
Notice of Disagreement within thirty (30)&nbsp;days after delivery of such Notice of Disagreement, the Sellers and the Purchaser shall, within thirty (30)&nbsp;days following the expiration of such 30-day period, engage the Accounting Referee,
pursuant to an engagement agreement executed by the Sellers, the Purchaser and the Accounting Referee, to resolve any Unresolved Objections. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;The Accounting Referee shall be instructed only to resolve the Unresolved Objections based on
written information to be provided to, or presentations made to, the Accounting Referee by the Sellers and the Purchaser and shall be instructed not to otherwise investigate any other matter independently. The Sellers and the Purchaser shall request
that the Accounting Referee make a final determination (which determination shall be binding on the parties hereto) of the Unresolved Objections within thirty (30)&nbsp;days from the date the Unresolved Objections and presentations were
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
submitted to the Accounting Referee and such final determination shall be deemed the Final Working Capital Statement. During the 30-day review by the Accounting Referee, the Sellers and the
Purchaser shall each make available to the Accounting Referee such individuals and such information, books and records as may be reasonably required by the Accounting Referee to make its final determination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;The resolution by the Accounting Referee of the Unresolved Objections shall be conclusive and
binding upon the parties hereto absent manifest error or fraud. The parties hereto agree that the procedure set forth in this <U>Section 2.5(d)</U> for resolving disputes with respect to the Working Capital Amount and the Cash and Cash Equivalents
shall be the sole and exclusive method for resolving any such disputes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;The fees and expenses
of the Accounting Referee will be allocated to and paid by the Purchaser, on the one hand, and the Sellers, on the other hand, based upon the relative success (in terms of percentages) of the aggregate of each of the Purchaser&#146;s and the
Sellers&#146; claims, as determined by the Accounting Referee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Initial Working Capital
Statement, including any modifications resulting from the resolution of any Disputed Items set forth in the Notice of Disagreement, shall be deemed to be the Final Working Capital Statement and be binding on the parties hereto for the purposes of
this <U>Section 2.5</U> upon the earliest to occur of: (i)&nbsp;the delivery by the Sellers of the Notice of Acceptance or the failure of the Sellers to deliver the Notice of Disagreement by the Objection Deadline Date pursuant to <U>Section
2.5(c)</U>; (ii)&nbsp;the resolution of all Disputed Items by the Sellers and the Purchaser pursuant to <U>Section 2.5(d)(ii)</U>; and (iii)&nbsp;the resolution of all Disputed Items pursuant to <U>Section 2.5(d)(v)</U> by the Accounting Referee.
Within five (5) Business Days after the Final Working Capital Statement becomes or is deemed final and binding on the parties hereto, an adjustment to the Purchase Price and a payment by wire transfer in respect thereof described below shall be made
as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;If the Closing Cash Adjustment is positive, within five (5) Business Days of the
final determination of all amounts covered in the Initial Working Capital Statement, the Purchaser shall pay to the Sellers an amount equal to the Closing Cash Adjustment, which amount shall be paid to each Seller based on his or its Pro Rata Share
of the Closing Cash Adjustment by wire transfer to the Wire Transfer Instructions; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If the
Closing Cash Adjustment is negative, then an amount in cash equal to the absolute amount of the Closing Cash Adjustment shall be paid to the Purchaser by the Escrow Agent from the Escrow Account, and in the event that the Closing Cash Adjustment
owed to the Purchaser exceeds the Escrow Fund, the Purchaser may seek payment of any such excess directly from the Sellers. Any payment required under this <U>Section 2.5(e)(ii)</U> shall be made within five (5) Business Days of the final
determination of all amounts covered in the Initial Working Capital Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;If the delivery deadline date for the Initial Working
Capital Statement or the Objection Deadline Date is a day that is not a Business Day, the applicable delivery deadline date shall be the immediately following Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Withholding.</B> The Purchaser shall be entitled to deduct and withhold from any consideration payable
pursuant to or as contemplated by this Agreement such amounts as are required to be deducted or withheld therefrom or in connection therewith under the Code or Treasury Regulations or any other provision of Applicable Law. Subject to the receipt of
the applicable FIRPTA Certificate and Form W-9 or Form W-8BEN-E with respect to each Seller, the Purchaser shall use its reasonable best efforts to consult in good faith with Sellers regarding any such withholding and to cooperate with Sellers to
take reasonable actions requested by Sellers as will enable the Purchaser, TangenX and/or the Sellers to take advantage of any exemption from or reduction in such Taxes under any applicable double taxation agreement or treaty. Such amounts shall be
treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.7&nbsp;&nbsp;&nbsp;&nbsp;Closing and Closing Deliveries. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing and Closing Date</U>. The closing of the transactions contemplated by this Agreement (the
&#147;<B>Closing</B>&#148;) shall take place on the date hereof via the exchange of documents and signatures in portable document file (PDF) format. The Closing shall be effective as of 11:59 P.M. (Eastern Standard Time) on the date of Closing and
such date is referred to in this Agreement as the &#147;<B>Closing Date</B>.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
Deliveries by the Sellers</U>. At the Closing, the Sellers shall deliver to the Purchaser each and all of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;A certificate of good standing for TangenX dated within ten (10) calendar days of the Closing Date
issued by the Secretary of State of the Commonwealth of Massachusetts; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;A pay-off letter, in
form and substance reasonably satisfactory to the Purchaser, from each Person who holds any Estimated Indebtedness listed on <B><U>Schedule 2.7(b)(ii)</U></B>, together with evidence in form and substance reasonably satisfactory to the Purchaser
that all Encumbrances have been fully and finally released; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Copies of the executed third
party consents, approvals, assignments, waivers or authorizations set forth on <B><U>Schedule 2.7(b)(iii)</U></B><B> </B>relating to TangenX, in form and substance reasonably satisfactory to the Purchaser;<B></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;Evidence in form and substance reasonably satisfactory to the Purchaser that each of the agreements
and arrangements set forth on <B><U>Schedule</U></B><B><U>&nbsp;</U></B><B><U>2.7(b)(iv)</U></B><B> </B>have been terminated in their entirety with no further Liabilities to TangenX;<B></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;An Intellectual Property Assignment Agreement, in
substantially the form attached hereto as <B><U>Appendix D</U></B>, executed by Groupe Novasep SAS and TangenX; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;Letters of resignation of all members of the board of directors and officers of TangenX in form and
substance reasonably satisfactory to the Purchaser; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;The Estimated Working Capital Statement;
and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;Such other documents as are reasonably necessary or appropriate to effect the
consummation of the transactions contemplated hereby relating to TangenX or which may be customary under local law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing Deliveries by Novasep</U>. At the Closing, Novasep shall deliver to the Purchaser each
and all of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Copies of the certificates evidencing the Novasep-Owned Stock. Upon
Novasep&#146;s receipt of its consideration set forth on <B><U>Appendix C</U></B>, Novasep shall deliver the original certificates evidencing the Novasep-Owned Stock duly endorsed by Novasep in blank or accompanied by a stock power duly executed by
Novasep, together with a Form W-8BEN-E from Novasep; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;A certificate of good standing for
TangenX Holding dated within ten (10) calendar days of the Closing Date issued by the Secretary of State of the State of Delaware; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Copies of the executed third party consents, approvals, assignments, waivers or authorizations set
forth on <B><U>Schedule 2.7(c)(iii)</U></B>, in form and substance reasonably satisfactory to the Purchaser; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;Duly executed letters of resignation of all members of the board of directors and officers of
TangenX Holding in form and substance reasonably satisfactory to the Purchaser; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;The Escrow
Agreement, duly executed by the Escrow Agent and Novasep; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;A certificate, in a form reasonably
satisfactory to Purchaser, issued by each of TangenX Holding and TangenX conforming to the requirements of Treasury Regulation Sections 1.1445-2(c)(3) and 1.897-2(h) and (ii) a notice to the Internal Revenue Service, in accordance with the
requirements of proof reasonably satisfactory to Purchaser that TangenX Holding and TangenX, as applicable, has provided notice of such statement to the Internal Revenue Service pursuant to Treasury Regulation Section 1.897-2(h)(2) dated as of the
Closing Date, in a form reasonably satisfactory to Purchaser, together with written authorization for Purchaser to deliver such notice to the Internal Revenue Service on behalf of TangenX Holding and TangenX, as applicable, after the Closing (the
&#147;<B>FIRPTA Certificate</B>&#148;); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;Such other documents as are reasonably necessary or
appropriate to effect the consummation of the transactions contemplated hereby relating to TangenX Holding or which may be customary under local law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing Deliveries by Connors</U>. At the Closing, Connors shall deliver to the Purchaser each
and all of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The original certificates evidencing the Connors-Owned Stock duly
endorsed by Connors in blank or accompanied by a stock power duly executed by Connors, together with a Form W-9 from Connors; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;An employment agreement and associated employment-related documents (including the Purchaser&#146;s
form of confidentiality and assignment of inventions agreement), each in the form attached hereto as <B>Appendix J</B>, executed by Connors; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The Escrow Agreement, duly executed by the Escrow Agent and Connors; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;Such other documents as are reasonably necessary or appropriate to effect the consummation of the
transactions contemplated hereby or which may be customary under local law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
Deliveries by the Purchaser</U>. At the Closing, the Purchaser shall execute and deliver to the Sellers each and all of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Payment of the Closing Cash Consideration in the manner set forth in
<U>Section</U><U>&nbsp;</U><U>2.3</U> of this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The Escrow Agreement, duly executed
by the Escrow Agent and the Purchaser; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Such other documents as are reasonably necessary
or appropriate to effect the consummation of the transactions contemplated hereby or which may be customary under local law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF THE SELLERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an inducement for the Purchaser to enter into this Agreement and to consummate the transactions contemplated hereby, the Sellers represent
and warrant to the Purchaser that each and all of the following representations and warranties (as modified by the Schedules to this Agreement (the &#147;<B>Schedules</B>&#148;)) are true and correct as of the date of this Agreement; provided,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
however, that, except as specifically provided in this <U>Article 3</U>, (i) Connors is making the representations and warranties with respect to himself and TangenX only, and not with respect to
Novasep or TangenX Holding, and (ii) Novasep is making the representations and warranties with respect to itself, TangenX Holding and TangenX, and not with respect to Connors. The Schedules shall be arranged to correspond to the sections and
subsections contained in this <U>Article 3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1&nbsp;&nbsp;&nbsp;&nbsp;Organization. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>TangenX Holding</U>. TangenX Holding is a corporation duly organized, validly existing, and in
good standing under the laws of the State of Delaware. TangenX Holding has all requisite power and authority, corporate and otherwise, to own its properties and assets now owned by it. TangenX Holding was incorporated on November 10, 2016 solely for
the purpose of engaging in the Reorganization and the transactions contemplated by this Agreement. As of the date of this Agreement, except for obligations or liabilities incurred in connection with its incorporation, the Reorganization and the
transactions contemplated by this Agreement, TangenX Holding has not signed any contract or entered into any arrangement or understanding or engaged in any business activity of any type or kind whatsoever. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>TangenX</U>.&nbsp;TangenX is a corporation duly organized, validly existing, and in good standing
under the laws of the Commonwealth of Massachusetts. TangenX has all requisite power and authority, corporate and otherwise, to own, operate and lease its properties and assets now owned, operated or leased by it, and to conduct the Business as it
is now being conducted. TangenX is duly qualified or authorized to do business and is in good standing under the Applicable Laws of each jurisdiction in which the conduct of its Business or the ownership, operation or lease of its properties and
assets requires such qualification or authorization, except where the failure to be so qualified, authorized or in good standing would not be material to TangenX.&nbsp;TangenX has made available to the Purchaser a true, correct and complete copy of
the articles of organization, bylaws and other organizational documents, each as in effect on the date hereof, of TangenX. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Novasep</U>. Novasep is a corporation duly organized, validly existing, and in good standing
under the laws of France. Novasep has all requisite power and authority, corporate and otherwise, to own, operate and lease its properties and assets now owned, operated or leased by it, and to conduct its business as it is now being conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2&nbsp;&nbsp;&nbsp;&nbsp;Capitalization.</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The authorized capital stock of TangenX Holding consists solely of 1,000 authorized shares of common
stock, with a par value of $0.01 per share. All 1,000 authorized shares of common stock of TangenX Holding are issued and outstanding and owned beneficially and of record by Novasep, free and clear of all Encumbrances. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The authorized capital stock of TangenX consists solely of 2,000 authorized shares of Class A voting
common stock, with no par value, and 198,000 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
authorized shares of Class B non-voting common stock, with no par value. Concerning the Class A voting common stock, 415 shares are issued and outstanding, with 100 shares owned beneficially and
of record by Connors, and 315 shares owned beneficially and of record by TangenX Holding, in each case free and clear of all liens and Encumbrances. Concerning the Class B non-voting common stock, 14,865 shares are issued and outstanding, and 3,000
shares are owned beneficially and of record by Connors and 11,865 shares are owned beneficially and of record by TangenX Holding, in each case free and clear of all Encumbrances.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The Novasep-Owned Stock held by Novasep was duly authorized for issuance and are validly issued,
fully paid and non-assessable. No Novasep-Owned Stock has been issued in violation of any securities laws or the rights of any Person. There are (i) no convertible securities outstanding or employee equity plans or any similar plan or agreement that
is intended to simulate equity ownership of TangenX Holding, (ii) no Rights outstanding or obligations to issue any shares, Rights or convertible securities, and (iii) no shareholder agreements or other agreements, understandings or commitments
relating to the rights of Novasep to vote or dispose of the Novasep-Owned Stock or to receive any portion of the Purchase Price. There are no declared but unpaid dividends with respect to the Novasep-Owned Stock. TangenX Holding does not own any
shares of stock or other securities or equity interests, directly or indirectly, in any other Person. TangenX Holding has not loaned any funds to any Person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The Connors-Owned Stock held by Connors and the shares of common stock of TangenX held by TangenX
Holding were duly authorized for issuance and are validly issued, fully paid and non-assessable. No Connors-Owned Stock or shares of common stock of TangenX held by TangenX Holding have been issued in violation of any securities laws or the rights
of any Person. Except as set forth in <B><U>Schedule</U></B><B><U>&nbsp;</U></B><B><U>3.2</U></B>, there are (i) no convertible securities outstanding or employee equity plans or any similar plan or agreement that is intended to simulate equity
ownership of TangenX, (ii) no Rights outstanding or obligations to issue any shares, Rights or convertible securities, and (iii) no shareholder agreements or other agreements, understandings or commitments relating to the rights of the Sellers to
vote or dispose of the Connors-Owned Stock or the shares of common stock of TangenX held by TangenX Holding, or to receive any portion of the Purchase Price. There are no declared but unpaid dividends with respect to the Connors-Owned Stock or the
shares of common stock of TangenX held by TangenX Holding. TangenX does not own any shares of stock or other securities or equity interests, directly or indirectly, in any other Person. Except as set forth in <B><U>Schedule 3.2</U></B>, TangenX has
not loaned any funds to any Person (other than advances to employees in the Ordinary Course of Business). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3&nbsp;&nbsp;&nbsp;&nbsp;Due Authorization.</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The execution, delivery and performance by Novasep, TangenX, and TangenX Holding of this Agreement
and the Ancillary Documents to which they are parties, and the consummation of the transactions contemplated hereby and thereby, have been duly and validly authorized by all necessary corporate action (if applicable) on the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
part of Novasep, TangenX and TangenX Holding. This Agreement and the Ancillary Documents have been duly and validly authorized, executed and delivered by Novasep, TangenX and TangenX Holding and
the obligations of Novasep, TangenX and TangenX Holding hereunder and thereunder are or will be, upon such execution and delivery (and assuming due authorization, execution and delivery by the other parties hereto and thereto), valid, legally
binding and enforceable against Novasep, TangenX and TangenX Holding in accordance with their respective terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Connors has all necessary capacity required for the execution, delivery and performance by Connors
of this Agreement and the Ancillary Documents to which he is a party, and the consummation by Connors of the transactions contemplated hereby and thereby. This Agreement and the Ancillary Documents have been duly and validly authorized, executed and
delivered by Connors, and the obligations of Connors hereunder and thereunder are or will be, upon such execution and delivery (and assuming due authorization, execution and delivery by the other parties hereto and thereto), valid, legally binding
and enforceable against Connors in accordance with their respective terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4&nbsp;&nbsp;&nbsp;&nbsp;Lawful Performance.</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Novasep has full power and authority to sell, assign, transfer, convey and deliver the Novasep-Owned
Stock to the Purchaser and to otherwise perform its obligations under this Agreement and the Ancillary Documents to which it is a party. The execution, delivery and performance of this Agreement and the Ancillary Documents to be executed, delivered
and performed by Novasep, TangenX and TangenX Holding pursuant to this Agreement and the Ancillary Documents, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (i)&nbsp;violate any provision of any
agreement entered into by Novasep with respect to the Novasep-Owned Stock or the organizational documents of TangenX or TangenX Holding; (ii) result in a violation or breach of any of the terms, conditions or provisions of, or give rise to any
termination or cancellation, or acceleration of any obligation under, any note, bond, mortgage, indenture, license, franchise, Permit (including, but not limited to, any Permits, approvals or authorizations of any Governmental Body), lease or other
Contract to which TangenX is a party or to which Novasep is a party with respect to the Novasep-Owned Stock, or by which they or any of their properties or assets may be bound; (iii) violate any Applicable Laws; or (iv) result in the creation of any
Encumbrances upon any shares of Novasep-Owned Stock or any Encumbrance upon any of TangenX&#146;s assets or properties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Connors has full power and authority to sell, assign, transfer, convey and deliver the Connors-Owned
Stock to the Purchaser and to otherwise perform his obligations under this Agreement and the Ancillary Documents to which he is a party. The execution, delivery and performance of this Agreement and the Ancillary Documents to be executed, delivered
and performed by Connors and TangenX pursuant to this Agreement and the Ancillary Documents, and the consummation of the transactions contemplated hereby and thereby, do not and will not:&nbsp;(i)&nbsp;violate any provision of any agreement entered
into by Connors or the organizational documents of TangenX; (ii) result in a violation or breach of any of the terms, conditions or provisions of, or give rise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
to any termination or cancellation, or acceleration of any obligation under, any note, bond, mortgage, indenture, license, franchise, Permit (including, but not limited to, any Permits, approvals
or authorizations of any Governmental Body), lease or other Contract to which TangenX is a party or to which Connors is a party, or by which they or any of their properties or assets may be bound; (iii) violate any Applicable Laws; or (iv) result in
the creation of any Encumbrances upon any shares of Connors-Owned Stock or any Encumbrance upon any of TangenX&#146;s assets or properties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The execution, delivery and performance by Novasep, TangenX and TangenX Holding of this Agreement
and each Ancillary Document to which they are parties, as applicable, do not and will not require any consent, approval, authorization or other order or declaration of, action by, filing with or notification to any Governmental Body or any other
Person other than those consents set forth in <B><U>Schedule 3.13</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The execution,
delivery and performance by Connors and TangenX of this Agreement and each Ancillary Document to which they are parties, as applicable, do not and will not require any consent, approval, authorization or other order or declaration of, action by,
filing with or notification to any Governmental Body or any other Person other than those consents set forth in <B><U>Schedule 3.13</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5&nbsp;&nbsp;&nbsp;&nbsp;Litigation.</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth on <B><U>Schedule 3.5</U></B>, there is no Proceeding pending or, to the
Knowledge of the Sellers, Threatened, and, in the past three (3) years, there has not been any Proceeding involving claims in excess of $25,000, with respect to (i) the Business, or (ii) the operations, assets or properties of TangenX. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;There is no Proceeding pending or, to the Knowledge of Novasep, Threatened, and, in the past three
(3) years, there has not been any Proceeding involving claims in excess of $25,000, (i) with respect to&nbsp;the transactions contemplated by this Agreement; or (ii) against Novasep that would reasonably be expected to adversely affect or restrict
Novasep&#146;s ability to enter into and perform Novasep&#146;s obligations under this Agreement or any Ancillary Document to which it is a party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;There is no Proceeding pending or, to the Knowledge of Connors, Threatened, and, in the past three
(3) years, there has not been any Proceeding involving claims in excess of $25,000, (i) with respect to the transactions contemplated by this Agreement; or (ii) against Connors that would reasonably be expected to adversely affect or restrict
Connors&#146; ability to enter into and perform Connors&#146; obligations under this Agreement or any Ancillary Document to which he is a party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Employment and Benefit Matters. </B><B><U>Schedule 3.6</U></B> lists all of TangenX&#146;s employees as
of the date of this Agreement, setting forth for each employee: his or her position or title; whether classified as exempt or non-exempt for wage and hour purposes; whether paid on a salary, hourly or commission basis and the employee&#146;s actual
annual base salary or other rates of compensation; and business location. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Employment Proceedings</U>. Except as otherwise
disclosed on <B><U>Schedule</U></B><B><U>&nbsp;</U></B><B><U>3.6(a)</U></B>, there is no, and within the past three (3) years there has not been any, Proceeding pending or, to the Knowledge of the Sellers, Threatened by any Person against TangenX,
or any of its respective current or former officers or directors relating to employment or labor matters, including with respect to the classification of independent contractors, equal employment opportunity, discrimination, harassment, wrongful
discharge, unfair labor practices, immigration, wages, hours, benefits, collective bargaining, the payment of social security or similar Taxes, occupational safety and health or plant closings. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Benefit Plans</U>.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in <B><U>Schedule 3.6(b)(i)</U></B>, TangenX has not maintained or contributed
to, or could have any Liability with respect to any Benefit Plans. TangenX does not and will not have any unfunded Liability for services rendered prior to the Closing Date under any Benefit Plans.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Each Benefit Plan that is intended to qualify under Section 401(a) of the Code has received a
favorable determination or approval letter from the Internal Revenue Service with respect to such qualification, and, to the Knowledge of the Sellers, and except as otherwise disclosed on
<B><U>Schedule</U></B><B><U>&nbsp;</U></B><B><U>3.6(b)(iii)</U></B>, no event or omission has occurred that would cause any Benefit Plan to lose such qualification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise disclosed on <B><U>Schedule 3.6(b)(iii)</U></B>, each Benefit Plan is, and has
been operated in material compliance with Applicable Laws and regulations and is and has been administered in all material respects in accordance with Applicable Laws and regulations and with its terms. There are no actions, suits, disputes,
arbitrations, audits or other governmental proceedings or other claims pending or, to the Knowledge of the Sellers, Threatened with respect to any Benefit Plan, and, to the Knowledge of the Sellers, there is no reasonable basis for any such action
or Proceeding. All payments and/or contributions required to have been made with respect to all Benefit Plans either have been made or have been accrued in accordance with the terms of the applicable Benefit Plan and Applicable Law. Each Benefit
Plan (or TangenX&#146;s participation therein) may be amended, terminated, or otherwise modified by TangenX to the greatest extent permitted by Applicable Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;Neither TangenX nor any ERISA Affiliate has ever maintained or contributed to any employee benefit
plan that is or was subject to Title IV of ERISA, Section 412 of the Code, Section 302 of ERISA or is a Multiemployer Plan and neither TangenX nor any ERISA Affiliate has ever incurred any Liability under Title&nbsp;IV of ERISA.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;None of the Benefit Plans provides health care or any other non-pension benefits to any employees
after their employment is terminated (other than as required by COBRA or similar state law) and TangenX has never promised to provide such post-termination benefits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;No Benefit Plan is subject to the laws of any
jurisdiction outside the United States.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;Each Benefit Plan that constitutes in any part a
nonqualified deferred compensation plan within the meaning of Section 409A of the Code has been operated and maintained in all material respects in operational and documentary compliance with Section 409A of the Code and applicable guidance
thereunder.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Triggering of Obligation and Other Binding Commitments</U>. Except as otherwise
disclosed on <B><U>Schedule 3.6(c)</U></B>, the consummation of the transactions described in this Agreement, in and of themselves, or in conjunction with any other event which has occurred on or prior to the Closing Date, will not (i) entitle any
employee or former employee of TangenX to severance pay, deal bonuses, unemployment compensation, or any other similar payment, or accelerate the time of payment or vesting of any compensation (including equity compensation), or increase the amount
of compensation due to any such employee or former employee, (ii) result in any &#147;parachute payment&#148; as defined in Section 280G(b)(2) of the Code (whether or not such payment is considered to be reasonable compensation for services
rendered); or (iii) result in a requirement to pay any Tax &#147;gross-up&#148; or similar &#147;make-whole&#148; payments to any employee, director or consultant of TangenX. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Labor Matters</U>. TangenX is not, and within the past three (3) years has not been, a party to,
or otherwise obliged under, any collective bargaining or similar agreement or other labor union contract applicable to persons employed by TangenX, and currently there are no organizational campaigns, petitions or other unionization activities
seeking recognition of a collective bargaining unit which could affect TangenX.&nbsp;There are no controversies, strikes, slowdowns or work stoppages active, pending or, to the Knowledge of the Sellers, Threatened between TangenX and any of its
employees, and TangenX has not experienced any such controversy, strike, slowdown or work stoppage within the past three (3) years. TangenX has paid, or prior to the Closing Date will pay, in full to all its employees or adequately accrued for all
wages, salaries, commissions, bonuses, benefits and other compensation due to or on behalf of its current or former employees and Contingent Workers (the &#147;<B>Accrued Compensation Amounts</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Contingent Workers</U>.<U> </U><B><U>Schedule 3.6(e)</U></B> contains a complete and accurate
list of all of the independent contractors, consultants, temporary employees, leased employees or other agents employed or used by TangenX and classified by TangenX as other than employees, or compensated other than through wages paid by TangenX
through TangenX&#146;s payroll department (&#147;<B>Contingent Workers</B>&#148;), showing for each Contingent Worker such individual&#146;s role in the business, fee or compensation arrangements and other contractual terms with TangenX.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>FLSA</U>.&nbsp;TangenX currently classifies and has
properly classified each of its employees as exempt or non-exempt for the purposes of the Fair Labor Standards Act and state, local and foreign wage and hour laws, and is and has been otherwise in compliance with such laws.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Classification of Workers</U>. To the extent that any Contingent Workers are or were engaged by
TangenX, TangenX currently classifies and has properly classified and treated them as Contingent Workers (as distinguished from Form W-2 employees) in accordance with Applicable Law and for the purpose of all employee benefit plans and
perquisites.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Applicable Laws</U>. To the Knowledge of the Sellers, TangenX is, and for the
past three (3) years has been, in compliance in all material respects with all Applicable Laws and regulations respecting labor and employment matters, including with respect to equal employment opportunity, discrimination, harassment, wrongful
discharge, unfair labor practices, immigration, wages, hours, benefits, collective bargaining, the payment of social security or similar Taxes, occupational safety and health or plant closings. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>WARN Act</U>. TangenX has not experienced a &#147;plant closing,&#148; &#147;business
closing,&#148; or &#147;mass layoff&#148; or similar group employment loss as defined in the federal Worker Adjustment and Retraining Notification Act (the &#147;<B>WARN Act</B>&#148;) or any similar state, local or foreign law or regulation
affecting any site of employment of TangenX or one or more facilities or operating units within any site of employment or facility of TangenX.&nbsp;During the ninety (90) day period preceding the date hereof, no more than five (5) employees has
suffered an &#147;employment loss&#148; as defined in the WARN Act with respect to TangenX. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Tax
Matter</B><B>s. </B>For purposes of this <U>Section 3.7</U>, (i) Connors is making the representations and warranties with respect to himself and TangenX only, and not with respect to Novasep or TangenX Holding, and (ii) Novasep is making the
representations and warranties with respect to itself, TangenX Holding and TangenX, and not with respect to Connors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax Returns</U>. Except as otherwise disclosed on <B><U>Schedule 3.7(a)</U></B>, each of TangenX
and TangenX Holding has timely filed with the appropriate taxing authorities all income and other material Tax Returns that are required to be filed by, or with respect to, TangenX or TangenX Holding, as applicable. Such Tax Returns are true,
correct and complete in all material respects and have accurately reflected all material Liability for Taxes of TangenX or TangenX Holding, as applicable, for the periods covered thereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment of Taxes</U>. All Taxes and Tax Liabilities of each of TangenX and TangenX Holding due
and owing have been timely paid to the proper taxing authority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Tax Matters</U>.
Neither TangenX nor TangenX Holding has been the subject of a dispute or claim or an audit or other examination of Taxes by the taxing authorities of any Governmental Body, or has received any written notices from any such taxing authority. Neither
TangenX nor TangenX Holding has entered into an agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or waiver or been requested to enter into an agreement or waiver extending any statute of limitations relating to the payment or collection of Taxes of such entity. Neither TangenX nor TangenX
Holding is presently contesting any Tax liability before any Governmental Body. All Taxes which each of TangenX and TangenX Holding is (or has been) required by law to withhold or collect have been duly withheld or collected, and have been timely
paid over and properly reported to the proper Governmental Body. There are no Tax sharing, allocation, indemnification or similar agreements in effect as between TangenX or TangenX Holding and any other party under which the Purchaser or TangenX or
TangenX Holding could be liable for any Taxes or other claims of any Person. Neither TangenX nor TangenX Holding has a request for a private letter ruling, a request for administrative relief, a request for technical advice, a request for a change
of any method of accounting, or any other request that is pending with any taxing authority that relates to Taxes or Tax Returns of such entity.&nbsp;No power of attorney granted by TangenX or TangenX Holding with respect to any Taxes is currently
in force.&nbsp;No claim has ever been made by a Governmental Body in a jurisdiction where TangenX or TangenX Holding does not file Tax Returns that TangenX or TangenX Holding is or may be subject to taxation in such jurisdiction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Encumbrances</U>. There are no Encumbrances for Taxes on any of the assets of TangenX or TangenX
Holding, other than statutory liens for current Taxes that are not yet due and payable that have been fully accrued on the books of TangenX or TangenX Holding, as applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax Reserves</U>. The unpaid Taxes of each of TangenX and TangenX Holding did not, as of the date
of the most recent Balance Sheet, exceed the accruals and reserves for Taxes (excluding accruals and reserves for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the face of such Balance Sheet
(rather than in any notes thereto) and will not exceed that reserve as adjusted for operations and transactions entered into in the Ordinary Course of Business through the Closing Date in accordance with the past custom and practice of such entity
in filing its Tax Returns. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Copies of Tax Returns</U>. Each of TangenX and TangenX Holding
has made available to the Purchaser true, correct and complete copies of income Tax Returns and all other material Tax Returns relating to such entity for each of the preceding four (4) taxable years, if applicable. Since TangenX Holding was formed
on November 10, 2016, TangenX Holding has not filed any Tax Returns. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Timing Matters</U>.
Neither TangenX nor TangenX Holding will be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any:&nbsp;(i)
change in method of accounting for a taxable period ending on or prior to the Closing Date, (ii) use of an improper method of accounting for a taxable period ending on or prior to the Closing Date, (iii) &#147;closing agreement&#148; as described in
Code Section 7121 (or any corresponding or similar provision of U.S. state, local or non-U.S. law) executed on or prior to the Closing Date, (iv) installment sale or open transaction disposition made on or prior to the Closing Date, (v) prepaid
amount or any other income eligible for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
deferral under the Code or Treasury Regulations promulgated thereunder (including, without limitation, pursuant to Code Sections 455 or 456, Treasury Regulations Section 1.451-5 and Revenue
Procedure 2004-34, 2004-33 I.R.B. 991) received on or prior to the Closing Date, (vi) election made under Code Section 108(i) prior to the Closing Date, or (vii) any similar election, action, or agreement that would have the effect of deferring any
Liability for Taxes of TangenX or TangenX Holding, as applicable, from any period ending on or before the Closing Date to any period ending after such date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Successor Liability</U>. Neither TangenX (including any predecessor of TangenX) nor TangenX
Holding (i) has ever been a member of a combined, consolidated, affiliated or unitary group for Tax purposes and (ii) has Liability for Taxes of any Person under Treasury Regulations Section 1.1502-6 (or any comparable provision of local, state or
non-U.S. law), as a transferee or successor, by Contract, or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Listed
Transactions</U>. Neither TangenX nor TangenX Holding is a party to, has participated in, or is currently participating in, a &#147;listed transaction&#148; (as defined in Section 6707A(c)(2) of the Code and Treasury Regulations Section
1.6011-4(b)(2)). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax Classification</U>. TangenX has been taxed as a C corporation for U.S.
federal income Tax purposes since September 1, 2006, and TangenX Holding has been taxed as a C corporation for U.S. federal income Tax purposes since November 10, 2016. Neither TangenX nor TangenX Holding has a permanent establishment or conducts
business through any branch other than its country of formation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>Spin Offs</U>. Neither
TangenX nor TangenX Holding has ever been either a &#147;distributing corporation&#148; or a &#147;controlled corporation&#148; within the meaning of Section&nbsp;355 of the Code and the Treasury Regulations promulgated thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<U>Joint Ventures</U>. Neither TangenX nor TangenX Holding has ever been party to any joint venture,
partnership or other arrangement or Contract treated as a partnership for federal income Tax purposes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<U>USRPHC</U>.&nbsp;Neither TangenX nor TangenX Holding is (or has ever been) a &#147;United States
real property holding company&#148; within the meaning of Section 897(c)(2) of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<U>Net
Operating Losses</U>. The net operating loss carryforwards (the &#147;<B>NOLs</B>&#148;) of TangenX, as set forth on <B><U>Appendix I</U></B>, are not subject to any limitation under Sections 382 or 384 of the Code, or otherwise; and there is no
Proceeding or investigation now pending or, to the Knowledge of the Sellers, Threatened against, with respect to or in limitation of the NOLs of TangenX as of the Closing Date, including, without limitation, any limitations under Sections&nbsp;382
or 384 of the Code (other than limitations incurred in connection with transactions effected pursuant to this Agreement).&nbsp;The NOLs on <B><U>Appendix I</U></B> accurately reflect the NOLs of TangenX as of the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.8&nbsp;&nbsp;&nbsp;&nbsp;No Guaranties.</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;TangenX has not guaranteed, or otherwise become contingently liable for, any Liability of any
Person. To the Knowledge of the Sellers, no event has arisen that would give rise to any obligation of guaranty on behalf of TangenX.&nbsp;TangenX is not subject to any obligation or requirement to provide funds to, or invest in, any other Person.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;TangenX Holding has not guaranteed, or otherwise become contingently liable for, any Liability
of any Person. To the Knowledge of Novasep, no event has arisen that would give rise to any obligation of guaranty on behalf of TangenX Holding. TangenX Holding is not subject to any obligation or requirement to provide funds to, or invest in, any
other Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Statements. </B>The Sellers have furnished (or made available) to the
Purchaser true and correct copies of the unaudited financial statements of TangenX for fiscal year 2015, consisting of the balance sheet of TangenX as of December&nbsp;31 in each of the years 2015, 2014, 2013 and 2012 and the related statements of
income and cash flow for the years then ended, and the unaudited financial statements of TangenX as of September 30, 2016, consisting of the balance sheet and the related statement of income and cash flow for the nine (9) month period then ended
(collectively, the &#147;<B>Financial Statements</B>&#148;).&nbsp;The unaudited balance sheet of TangenX as of December&nbsp;31 in each of the years 2015, 2014, 2013 and 2012, and unaudited balance sheet of TangenX as of September 30, 2016 are
collectively referred to hereinafter as the &#147;<B>Balance Sheets</B>.&#148;&nbsp;All of said Financial Statements, including any notes thereto, (i) fairly present, in all material respects, the financial position of TangenX as of the end of the
applicable fiscal period and the results of its operations for the applicable periods then ended, and (ii) have been prepared in accordance with generally accepted accounting principles applied by TangenX on a consistent basis throughout the periods
covered thereby, and on a basis consistent with that of prior years and periods, in each case subject to normal and recurring year-end adjustments and the absence of notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.10</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Absence of Certain Developments. </B>Except for the transactions contemplated by this Agreement, since
June 30, 2016 or as set forth in <B><U>Schedule 3.10</U></B>:&nbsp;(i) there has not been any development, change, effect, event, occurrence or circumstance (&#147;<B>Developments</B>&#148;) or combination of Developments affecting TangenX or its
business, condition (financial or other), operations, results of operations, assets, properties or Liabilities that has had, or is likely to have, a material adverse effect; and/or (ii) TangenX has conducted the Business in the Ordinary Course of
Business and has not: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;declared, set aside or paid a dividend or made any other distribution
with respect to any class of capital stock of TangenX; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;changed accounting methods or practices
(including, without limitation, any change in depreciation, amortization or cost accounting policies or rates), or changed its cash management policies, pricing, collection or payment policies, including by accelerating the collection of accounts
receivables or delaying the payment of accounts payable outside the Ordinary Course of Business; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;hired any Person, entered into any employment
contract, or Benefit Plan, written or oral, or entered into any other agreement relating to providing management and operating personnel; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;granted to any current or former director, officer or employee of TangenX any increase in wages or
bonus, severance, profit sharing, retirement, deferred compensation, insurance or other compensation or benefits; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;terminated the employment, changed the title, office or position, or materially reduced the
responsibilities of any officer, senior manager or key employee of TangenX; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;made any change or
amendment in its Articles of Organization or bylaws; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;issued or sold any securities, acquired,
directly or indirectly, by redemption or otherwise, any securities, or granted or entered into any options, warrants, calls or commitments of any kind with respect thereto; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;made any capital expenditure exceeding $25,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;made or changed any material Tax election, filed any amended Tax Return, entered into any agreement
(including, without limitation, a closing agreement) with respect to Taxes, surrendered any right to claim a refund of Taxes, consented to any extension or waiver of the limitations period applicable to any Tax claim or assessment, adopted or
changed any accounting methods, practices or periods for Tax purposes, made or requested any Tax ruling, entered into any Tax sharing or similar agreement or arrangement, entered into any transactions giving rise to a deferred gain or loss, or
settled any Tax claim or assessment; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;incurred any obligations for Indebtedness; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;transferred, leased, assigned, sold or otherwise disposed of any asset which is material to TangenX,
or transferred, assigned or granted any license or sublicense with respect to any Intellectual Property; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;acquired by merger or consolidation with, or by purchase of a substantial portion of the assets,
stock or equity interests of, or by any other manner, any business or any Person or any division thereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;suffered any damage, destruction or loss (whether or not covered by insurance) to its property
resulting in Liabilities in excess of $10,000; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;terminated, amended or entered into, or waived a
material right under, a Contract, or entered into any Contract with a Related Person; and/or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;agreed, whether in writing or otherwise, to do or commit to do or effect any of the foregoing except
as otherwise required under this Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.11&nbsp;&nbsp;&nbsp;&nbsp;Intellectual Property.</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Schedule 3.11(a)</U></B> contains a complete and accurate list of all (i) Patents owned by
TangenX or used or held for use by TangenX in the Business<B> </B>(&#147;<B>TangenX Patents</B>&#148;), registered Marks owned by TangenX or used or held for use by TangenX in the Business (&#147;<B>TangenX Marks</B>&#148;), (ii) products and/or
services currently or previously researched, designed, developed, manufactured, performed, licensed, sold, distributed and/or otherwise made commercially available by TangenX (the &#147;<B>Products</B>&#148;), (iii) licenses, sublicenses or other
agreements under which TangenX is granted rights by others in Intellectual Property&nbsp;(other than commercial off the shelf software that is made available for a total cost of less than $10,000), and (iv) licenses, sublicenses or other agreements
under which TangenX has granted rights to others in Intellectual Property. Except as set forth on <B><U>Schedule 3.11(a)</U></B>, all TangenX Intellectual Property owned or purported to be owned by TangenX that has been issued by, or registered
with, or the subject of an application filed with, as applicable, the U.S. Patent and Trademark Office or any similar office or agency anywhere in the world is registered in the name of TangenX.&nbsp;Except as set forth on <B><U>Schedule
3.11(a)</U></B>, TangenX does not own or hold for use in the Business any registered Copyrights or material unregistered Marks. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth on <B><U>Schedule 3.11(b)</U></B>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;with respect to the TangenX Intellectual Property owned or purported to be owned by TangenX, TangenX
exclusively owns such TangenX Intellectual Property free and clear of all Encumbrances; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;all
TangenX Intellectual Property owned by or exclusively licensed to TangenX that has been issued by, or registered with, or the subject of an application filed with, as applicable, the U.S. Patent and Trademark Office or any similar office or agency
anywhere in the world is currently in compliance with formal legal requirements (including without limitation, as applicable, payment of filing, examination and maintenance fees, inventor declarations, proofs of working or use, timely
post-registration filing of affidavits of use and incontestability, and renewal applications), and, to the Knowledge of the Sellers, all TangenX Intellectual Property owned by or exclusively licensed to TangenX is valid and enforceable; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;none of the TangenX Intellectual Property owned by or exclusively licensed to TangenX that has
been issued by, or registered by or the subject of an application filed with, as applicable, the U.S. Patent and Trademark Office or in any similar office or agency anywhere in the world is subject to any maintenance fees or Taxes or actions falling
due within ninety (90) days after the Closing Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;TangenX has all rights that are either
(A)&nbsp;necessary to use the TangenX Intellectual Property or (B) to the Knowledge of the Sellers, needed to conduct the Business, including valid licenses to use all of the software programs present on the computers and other software-enabled
electronic devices that TangenX owns or leases or that TangenX has otherwise provided to its employees </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
for their use, and valid licenses to use any Intellectual Property owned by others that is presently used or needed to conduct the Business, whether or not listed in <B><U>Schedule
3.11(a);</U></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;there are no pending or, to the Knowledge of the Sellers, Threatened claims
against TangenX alleging that (A) the operation of the Business or any activity by TangenX, (B) the manufacture, sale, offer for sale, importation, and/or use of any Product, or (C) the possession or use in the Business of any of the TangenX
Intellectual Property, infringes or violates (or in the past infringed or violated) the Intellectual Property rights of any other Person (&#147;<B>Third Party Intellectual Property</B>&#148;) or constitutes a misappropriation of (or in the past
constituted a misappropriation of) any subject matter of any Third Party Intellectual Property; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;neither the operation of the Business, nor any activity by TangenX, nor manufacture, use,
importation, offer for sale and/or sale of any Product infringes or violates (or in the past infringed or violated) any Third Party Intellectual Property or constitutes a misappropriation of (or in the past constituted a misappropriation of) any
subject matter of any Third Party Intellectual Property; <U>provided</U>, that, solely with respect to Patents, the foregoing representation is made only to the Knowledge of the Sellers; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;there are no pending, or to Knowledge of the Sellers, no Threatened claims against TangenX
alleging that any TangenX Intellectual Property is invalid or unenforceable; no TangenX Patent has been or is now involved in any interference, reissue, <FONT STYLE="white-space:nowrap">re-examination,</FONT> inter-partes review, post-grant review,
or opposition Proceeding; to the Knowledge of the Sellers, there is no Patent of any third party that potentially interferes with a TangenX Patent; all Products made, used or sold under the TangenX Patents have been marked with the proper patent
notice; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;TangenX is not obligated under any Contract or otherwise to pay royalties, fees or
other payments to any Person for the use of any Intellectual Property; TangenX has not entered into any agreement to indemnify any other Person against any claim of infringement or misappropriation of any Intellectual Property; there are no
settlements, covenants not to sue, consents, judgments, or orders or similar obligations that: (A) restrict TangenX&#146;s rights to use any Intellectual Property, (B) restrict TangenX&#146;s Business, in order to accommodate a third party&#146;s
Intellectual Property, or (C) permit third parties to use any TangenX Intellectual Property; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;&nbsp;TangenX has not licensed any TangenX Intellectual Property to others, has not otherwise allowed
others to use it and, to the Knowledge of the Sellers (A) there is no, nor has there been any, infringement or violation by any Person of any TangenX Intellectual Property or of TangenX&#146;s rights therein or thereto and (B) there is no, nor has
there been any, misappropriation by any Person of any TangenX Intellectual Property or the subject matter thereof; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;Connors and Mark Perreault are the only former or
current employees, consultants or contractors of TangenX that developed inventions relating to the business of TangenX and each of Connors and Mark Perreault has executed written instruments with TangenX that assign to TangenX all rights, title and
interest in and to any and all (A) inventions, improvements, ideas, discoveries, writings, works of authorship, other Intellectual Property, and information relating to the business of TangenX and any of the products or services being researched,
developed, manufactured or sold by TangenX or that may be used with any such products or services and (B)&nbsp;Intellectual Property relating thereto, and, except for Connors and Mark Perreault, no other former or current employees, consultants, or
contractors of TangenX has any right, title or interest in or to any (A) inventions, improvements, ideas, discoveries, writings, works of authorship, other Intellectual Property, or any of the products or services being researched, developed,
manufactured or sold by TangenX or that may be used with any such products or services or (B)&nbsp;Intellectual Property relating thereto; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi)&nbsp;&nbsp;&nbsp;&nbsp;TangenX has taken all reasonable security measures to protect the confidentiality and value of all
Trade Secrets owned by TangenX or used or held for use by TangenX in the Business (&#147;<B>TangenX Trade Secrets</B>&#148;), including, without limitation, requiring each TangenX employee with access to TangenX Trade Secrets to execute a binding
confidentiality agreement, copies or forms of which have been provided to the Purchaser and, to the Knowledge of the Sellers, there has not been any breach by any party to such confidentiality agreements; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii)&nbsp;&nbsp;&nbsp;&nbsp;each Product performs in all material respects in accordance with its documented specifications
and as TangenX has warranted to its customers; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;the consummation of the transactions
contemplated by this Agreement will not adversely affect the use by TangenX of any TangenX Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.12</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Compliance with Laws. </B>The Business is and has been operated and TangenX is and has been in
compliance in all material respects with the requirements of Applicable Laws to which TangenX is subject, and TangenX has not received any written notice of, and the Sellers have no Knowledge of, any violation of any Applicable Laws. None of the
representations and warranties contained in this <U>Section 3.12</U> shall be deemed to relate to employment and benefit matters (which are governed by <U>Section 3.6</U>), tax matters (which are governed by <U>Section 3.7</U>), or environmental
matters (which are governed by <U>Section 3.20</U>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.13</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Contracts. </B>All Contracts of TangenX are
set forth in <B><U>Schedule 3.13</U></B> and have been provided (or made available) to the Purchaser. All of the Contracts in <B><U>Schedule 3.13</U></B> were made in the Ordinary Course of Business and, to the Knowledge of the Sellers, are valid,
binding and currently in full force and effect. TangenX is not in material breach or default under any of the Contracts and, to the Knowledge of the Sellers, no event has occurred which, through the passage of time or the giving of notice, or both,
would constitute a breach or default by TangenX, or give rise to a right of termination or cancellation by another party under any of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Contracts, or cause the acceleration of any Liability of TangenX, or result in the creation of any Encumbrance upon any of the properties or assets of TangenX.&nbsp;Except as set forth in
<B><U>Schedule</U></B><B><U>&nbsp;</U></B><B><U>3.13</U></B>, none of the Contracts have been canceled, terminated, amended, assigned, or modified. Except as set forth in <B><U>Schedule 3.13</U></B>, the consummation of the transactions contemplated
hereby will not require the consent, waiver or approval of, or notice to, any Person under any of the Contracts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.14</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Real Estate. </B>TangenX does not currently own, and has never owned, any real property. The only real
estate which TangenX leases are two units both located at 910 Boston Turnpike Road, Shrewsbury, MA 01545 (the&nbsp;&#147;<B>Leased&nbsp;Property</B>&#148;). TangenX is not in default in the performance of any material obligation under the leases for
the Leased Property, and none of the other parties to such leases are in default in performance of their material obligations thereunder. Such leases are in full force and effect, and TangenX has not assigned its rights under such leases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.15</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Adequacy of Properties. </B>TangenX owns, leases or otherwise has adequate rights to use the assets and
tangible and intangible personal property necessary for the conduct of the Business in the manner in which such Business is presently being conducted with no material conflict with or infringement of the rights of others. TangenX has good, valid and
transferable title to, or valid and transferable lease hold interests in, all of its assets and tangible and intangible personal property, free and clear of all Encumbrances, and no Seller or any Affiliate of any Seller has any interest in such
assets and properties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.16</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Permits and Certificate Applications. </B>TangenX has timely obtained, or
applied and met the requirements for, all Permits of each Governmental Body having jurisdiction over TangenX, or any of its properties or assets, required to operate and carry on the Business as now being conducted and has timely applied to renew
any such Permits for which such renewal application is required. The Permits of TangenX are in full force and effect. TangenX has not received written notice that any Permit is being considered for non-renewal, termination, revocation or suspension
and there are no applications for Permits or Permit extensions pending before any Governmental Bodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.17&nbsp;&nbsp;&nbsp;&nbsp;Insurance. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Schedule 3.17</U></B> sets forth a list, as of the date hereof, of all insurance policies
maintained by TangenX or with respect to which TangenX is a named insured or otherwise the beneficiary of coverage. Such insurance policies are in full force and effect on the date of this Agreement, and effective until the Closing Date, and all
premiums due on such insurance policies have been paid. <B><U>Schedule 3.17</U></B> sets forth a list of all claims made under such insurance policies within the last two (2) years that exceed $25,000 individually. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;TangenX has promptly and adequately notified the insurance carriers of any and all claims known with
respect to the Business for which TangenX is insured and no insurance carrier has denied coverage or reserved its rights with respect to such claims. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in <B><U>Schedule 3.17</U></B>,
the consummation of the transactions contemplated by this Agreement will not result in the loss of insurance coverage for TangenX for occurrences prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.18</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Brokers. </B>Except for Brocair Partners LLC, neither the Sellers, TangenX, TangenX Holding nor any of
their Affiliates have employed or engaged any broker, finder, agent, banker or third party, nor have they otherwise dealt with anyone purporting to act in the capacity of a finder or broker in connection with the transactions contemplated hereby.
Except for the payment of fees to Brocair Partners LLC, no commissions, finder&#146;s fees or like charges have been or will be incurred by the Sellers, TangenX, TangenX Holding or any of their Affiliates in connection with the execution and
delivery of this Agreement or the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.19</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Relationship with Related Persons. </B>Except as set forth in <B><U>Schedule 3.19</U></B>, the Sellers,
their directors and officers (as applicable), and their Related Persons do not have any interest in or claim to any of the properties or assets of or used by TangenX and do not own, of record or as a beneficial owner, an equity interest or any other
financial or profit interest in any Person that has had business dealings or a financial interest in any transaction with TangenX.&nbsp;Except as set forth in <B><U>Schedule 3.19</U></B>, to the Knowledge of the Sellers, neither the Sellers, nor any
director or officer of any Seller that is an entity, and none of their Related Persons, is a party to any Contract with, or has any claim or right against, TangenX. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.20&nbsp;&nbsp;&nbsp;&nbsp;Environmental Matters.</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in <B><U>Schedule 3.20(a)</U></B>, TangenX:&nbsp;(i)&nbsp;has not transported,
stored, and/or disposed of any Hazardous Materials except in compliance with Environmental Laws, and has been and is in compliance in all material respects with all Environmental Laws; (ii) does not have Knowledge that the Leased Property is now
being used, or has ever been used, as a landfill, dump or other disposal, storage, transfer, treating or handling area for any Hazardous Materials; (iii) to the Knowledge of the Sellers, asbestos, polychlorinated biphenyls or urea formaldehyde has
not been placed, stored, located, or disposed on the Leased Property; (iv) to the Knowledge of the Sellers, there are currently no and there have never been any underground and/or above ground storage tanks (whether or not currently in use) on the
Leased Property; (v) to the Knowledge of the Sellers, the Leased Property does not contain Hazardous Materials that require remediation under Environmental Laws; and (vi) has not agreed to assume, and has not assumed by operation of law, any
environmental Liability of any other Person. The Sellers have provided or made available to the Purchaser all environmental audits, environmental risk assessments, site assessments, environmental Permits, health and safety plans and health and
safety incident reports relevant to the Business or to any property now or formerly owned, operated or leased by TangenX.&nbsp;TangenX has all required environmental Permits required to operate the Business.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in <B><U>Schedule 3.20(b)</U></B>, TangenX has not: (i) received written notice
under the citizen suit provisions of any Environmental Law; (ii) received any written notice, demand, complaint or claim under any Environmental Law; or (iii)&nbsp;to the Knowledge of Sellers, been subject to or threatened with any governmental or
citizen enforcement action with respect to any Environmental Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.21</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Absence of Undisclosed Liabilities. </B>TangenX has no
Liabilities or obligations, either accrued, absolute, contingent or otherwise except for Liabilities:&nbsp;(i) reflected or reserved against in the Balance Sheets as of their respective dates or in the notes thereto; or (ii) those which have been
incurred in the Ordinary Course of Business since June 30, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.22</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Capital Projects. </B>Except as
set forth on <B><U>Schedule 3.22</U></B>, TangenX has not planned any capital expenditures in excess of $25,000 during 2016 or the first six (6) months of 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.23</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Bank Accounts. </B><B><U>Schedule 3.23</U></B> lists the names, account numbers, authorized signatories
and locations of all banks and other financial institutions at which TangenX has an account or safe deposit box and the name of each Person authorized to draft on or have access to any such account or safe deposit box. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.24</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Indebtedness at Closing. </B>There is no Indebtedness due and owing from TangenX to any Person, there
are no pay-off letters relating to such Indebtedness, and as of the Closing there will be no monetary obligations of TangenX with respect to any such Indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.25&nbsp;&nbsp;&nbsp;&nbsp;Suppliers and Customers.</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Schedule 3.25(a)</U></B> sets forth a list of the top ten (10) suppliers by value of purchases
by TangenX (each, a &#147;<B>Supplier</B>&#148;) for the nine-month period ending September 30, 2016.&nbsp;In the prior three (3) years, no Supplier has terminated or materially reduced its business relationships with TangenX.&nbsp;There has been no
written or, to the Knowledge of Novasep, TangenX Holding or TangenX, any other communication from any Supplier which has been received by Novasep, TangenX or TangenX Holding stating that such Supplier is planning to terminate or materially reduce
its business relationships with TangenX.&nbsp;There has been no written or, to the Knowledge of Connors or TangenX, any other communication from any Supplier which has been received by Connors or TangenX stating that such Supplier is planning to
terminate or materially reduce its business relationships with TangenX.&nbsp;In the prior three (3) years, there has not been any material adverse change in relations with any Supplier. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Schedule 3.25(b)</U></B> sets forth a list of the top twenty-five (25) customers and/or
distributors by revenue of TangenX (each, a &#147;<B>Customer</B>&#148;) for the nine-month period ending September 30, 2016.&nbsp;In the prior three (3) years, no Customer has terminated or materially reduced its business relationships with
TangenX.&nbsp;There has been no written or, to the Knowledge of Novasep, TangenX Holding or TangenX, any other communication from any Customer which has been received by Novasep, TangenX or TangenX Holding stating that such Customer is planning to
terminate or materially reduce its business relationships with TangenX.&nbsp;There has been no written or, to the Knowledge of Connors or TangenX, any other communication from any Customer which has been received by Connors or TangenX stating that
such Customer is planning to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
terminate or materially reduce its business relationships with TangenX.&nbsp;Except as set forth on <B><U>Schedule 3.25(b)</U></B><B>,</B> in the prior three (3) years, there has not been any
material adverse change in relations with any Customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.26</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Accounts Receivable; Accounts Payable.
</B>All of the accounts receivable of TangenX were incurred in the Ordinary Course of Business and are valid and enforceable claims and are not subject to any setoff or counterclaim. Except as set forth in <B><U>Schedule 3.26</U></B>, TangenX has no
loans receivable from any Affiliate of any Seller or from any director, manager, officer or employee of any Seller or its Affiliates. Any reserve for doubtful accounts reflected in the Financial Statements has been determined in accordance with the
TangenX Accounting Practices and is adequate to account for such doubtful accounts. TangenX has collected its accounts receivable in the Ordinary Course of Business and has not accelerated any such collections. All accounts payable of TangenX arose
in bona fide arm&#146;s length transactions in the Ordinary Course of Business and no such account payable is delinquent by more than thirty (30) days in its payment. <B><U>Schedule 3.26</U></B> lists an accurate aging of any accounts receivable and
accounts payable outstanding as of the date hereof. Except as set forth on <B><U>Schedule 3.26</U></B>, TangenX has not provided any discounts, allowances, free Products, rebates or other promotions in connection with the sale of Products to any
Customer that could be a Liability of TangenX post-Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.27</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Warranties and Products. </B>There are
no existing or, to the Knowledge of the Sellers, Threatened claims against TangenX relating to any work performed by TangenX, product Liability, warranty or other similar claims against TangenX alleging that any Product is defective or fails to meet
any product or service warranties. To the Knowledge of the Sellers, there are (a) no material systemic or chronic problems with any current Product of TangenX, and (b) no material Liabilities for warranty or other material claims or returns with
respect to any Product of TangenX relating to any such defects or problems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.28</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Inventory. </B>All of
the Inventory consist of goods usable and/or saleable, and have all certifications necessary and sufficient for use and/or sale, in TangenX&#146;s Ordinary Course of Business. Purchase commitments for raw materials and parts are not in excess of
normal requirements and none are at prices materially in excess of current market prices. Since June 30, 2016, no Inventory has been sold or disposed of except through sales in the Ordinary Course of Business.&nbsp;&#147;<B>Inventory</B>&#148; means
all raw materials, works-in-progress, finished goods, supplies and other inventories of TangenX, wherever situated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.29</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Illegal Payment</B><B>s. </B>None of TangenX, any of its employees, officers, managers or directors and,
to the Knowledge of the Sellers, any third-party acting on behalf of TangenX,&nbsp;has taken or failed to take any action which would cause TangenX to be in violation of the Foreign Corrupt Practices Act of 1977, as amended (the
&#147;<B>FCPA</B>&#148;), or any rules or regulations thereunder if such law, rules and regulations were applicable thereto. None of TangenX, any of its employees, officers, managers or directors and, to the Knowledge of the Sellers, any third-party
acting on behalf of TangenX, has offered, paid, promised to pay, or authorized, or will offer, pay, promise to pay, or authorize, directly or indirectly, the giving of money or anything of value to any Official, or to any other Person while knowing
or being aware of a high probability that all or a portion of such money or thing of value will be offered, given or promised, directly or indirectly, to any Official, for the purpose of:&nbsp;(a)&nbsp;influencing any act or decision of such
Official in his, her or its official capacity, including a decision to fail to perform his, her or its official </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
duties or functions; or (b)&nbsp;inducing such Official to use his, her or its influence with any Governmental Body to affect or influence any act or decision of such Governmental Body, or to
obtain an improper advantage in order to assist TangenX, or any third-party in obtaining or retaining business for or with, or directing business to, TangenX.&nbsp;For purposes of this Agreement, an &#147;<B>Official</B>&#148; shall include any
appointed or elected official, any government employee, any political party, party official, or candidate for political office, or any officer, manager, director or employee of any Governmental Body. The Sellers shall be liable for any pre-Closing
breach by TangenX of any Applicable Laws pertaining to anticorruption, including the FCPA, in each of the jurisdictions in which TangenX currently does business or has done business in the five (5) years prior to the date hereof, either directly or
indirectly. To the Knowledge of the Sellers, no event, fact or circumstance has occurred in the three (3) years prior to the date hereof or exists that is reasonably likely to result in a finding of noncompliance with any Applicable Law relating to
anticorruption. Neither TangenX, nor any of its Representatives or, to the Knowledge of the Sellers, any third-party acting on behalf of TangenX, (i)&nbsp;has used or is using any corporate funds for any illegal contributions, gifts, entertainment
or other unlawful expenses relating to political activity, (ii)&nbsp;has used or is using any corporate funds for any direct or indirect unlawful payments to any foreign or domestic governmental officials or employees or any other Person,
(iii)&nbsp;has violated or is violating any provision of the FCPA, (iv)&nbsp;has established or maintained, or is maintaining, any unlawful fund of corporate monies or other properties, or (v)&nbsp;has made any bribe, unlawful rebate, payoff,
influence payment, kickback or other unlawful payment of any nature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.30</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Export Control Law</B><B>s.
</B>During the last five (5) years, TangenX has conducted its export transactions in accordance, in all material respects, with applicable provisions of United States export control laws and regulations.&nbsp;Without limiting the foregoing:
(a)&nbsp;TangenX has obtained all material export licenses and other material approvals required for its export of Products, software, and technologies from the United States; (b)&nbsp;TangenX is in compliance in all material respects with the terms
of all applicable material export licenses or other material approvals; (c)&nbsp;there are no pending or, to the Knowledge of the Sellers, Threatened claims against TangenX with respect to such material export licenses or other material approvals;
(d)&nbsp;to the Knowledge of the Sellers, there are no Proceedings, conditions, or circumstances pertaining to the export transactions of TangenX that would reasonably be expected to give rise to any material future claims; and (e)&nbsp;no consents
or approvals relating to any export licenses of TangenX are required in connection with the transactions contemplated hereby. <B><U>Schedule 3.30</U></B> sets forth an accurate and complete list of each of the countries to which TangenX has shipped
or distributed Products during the last five (5) years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.31&nbsp;&nbsp;&nbsp;&nbsp;Books and Records.</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Sellers have made available to the Purchaser true, correct and complete copies of all minutes
and corporate records of TangenX.&nbsp;At the Closing, all of those minute books and corporate records will be in the possession of TangenX. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Novasep has made available to the Purchaser true, correct and complete copies of all minutes and
corporate records of TangenX Holding. At the Closing, all of those minute books and corporate records will be in the possession of TangenX Holding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.32</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Other Representations and Warranties. </B>Except for the
representations and warranties contained in this <U>Article 3</U> (including the related portions of the Schedules), none of the Sellers, TangenX, TangenX Holding or any other Person has made or makes any other express or implied representation or
warranty, either written or oral, on behalf of the Sellers, TangenX or TangenX Holding, including any representation or warranty as to the accuracy or completeness of any information regarding TangenX furnished or made available to the Purchaser and
its Representatives (including any information, documents or material made available to the Purchaser in the Data Room, management presentations or in any other form in expectation of the transactions contemplated hereby) or as to the future
revenue, profitability or success of TangenX, or any representation or warranty arising from statute or otherwise in law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF THE PURCHASER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an inducement for the Sellers to enter into this Agreement and to consummate the transactions contemplated hereby, the Purchaser represents
and warrants to the Sellers that each and all of the following representations and warranties are true and correct as of the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Organization. </B>The Purchaser is a corporation duly organized, validly existing and in good standing
under the laws of the State of Delaware and has all requisite power and authority, corporate and otherwise, to own, operate and lease its properties and assets and to conduct its business as it is now being conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Due Authorization. </B>The execution, delivery and performance of this Agreement, and the Ancillary
Documents to be executed and delivered by the Purchaser pursuant to this Agreement, and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized by all necessary corporate action on the part of the
Purchaser. This Agreement and the Ancillary Documents have been duly and validly authorized; executed and delivered by the Purchaser and the obligations of the Purchaser hereunder and thereunder are or will be, upon such execution and delivery (and
assuming due authorization, execution and delivery by the other parties hereto and thereto), valid, legally binding and enforceable against the Purchaser in accordance with their respective terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Investment Purpose. </B>The Purchaser is acquiring the Stock solely for its own account for investment
purposes and not with a view to, or for offer or sale in connection with, any distribution thereof. The Purchaser acknowledges that the Stock is not registered under the Securities Act of 1933, as amended, or any state securities laws. The Purchaser
is able to bear the economic risk of holding the Stock for an indefinite period (including total loss of its investment), and has sufficient knowledge and experience in financial and business matters so as to be capable of evaluating the merits and
risk of its investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Lawful Performance. </B>The Purchaser has full power and authority to
perform its obligations under this Agreement and the Ancillary Documents. The execution, delivery and performance of this Agreement and the Ancillary Documents to be executed, delivered and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
performed by the Purchaser pursuant to this Agreement and the Ancillary Documents, and the consummation of the transactions contemplated hereby and thereby, do not and will not:&nbsp;(i) violate
any provision of any agreement entered into by the Purchaser; (ii) result in a violation or breach of any of the terms, conditions or provisions, or give rise to any termination or cancellation, or acceleration of any material obligation under, of
any note, bond, mortgage, indenture, license, franchise, Permit (including, but not limited to, any Permits, approvals or authorizations of any Governmental Body), lease or other Contract to which the Purchaser is a party, or by which it or any of
its properties or assets may be bound; or (iii) violate any Applicable Laws; in each case, which could materially and adversely affect the legality, validity or enforceability of this Agreement, any Ancillary Agreement or the consummation of the
transactions contemplated hereby or thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Available Fund</B><B>s. </B>As of the date of this
Agreement, the Purchaser has sufficient cash in immediately available funds to enable it to make payment of the Purchase Price and consummate the transactions contemplated hereby. The Purchaser confirms that it is not a condition to the Closing or
any of its other obligations under this Agreement for the Purchaser to obtain financing for or in connection with the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Brokers. </B>Except for EuroConsult Capital LLC, the Purchaser has not employed or engaged any broker,
finder, agent, banker or third party, nor has it otherwise dealt with anyone purporting to act in the capacity of a finder or broker in connection with the transactions contemplated hereby. Except for the payment of fees to EuroConsult Capital LLC,
no commissions, finder&#146;s fees or like charges have been or will be incurred by the Purchaser in connection with the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Litigation. </B>There is no Proceeding pending or, to the Knowledge of the Purchaser, Threatened (a)
against or by the Purchaser or any Affiliate of the Purchaser that challenges or seeks to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement; or (b) against the Purchaser that would reasonably be expected to adversely
affect or restrict the Purchaser&#146;s ability to enter into and perform the Purchaser&#146;s obligations under this Agreement or any Ancillary Document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Independent Investigation. </B>The Purchaser has conducted its own independent investigation, review and
analysis of the Business, results of operations, prospects, condition (financial or otherwise) and assets of TangenX and TangenX Holding. The Purchaser acknowledges and agrees that:&nbsp;(i) in making its decision to enter into this Agreement and to
consummate the transactions contemplated hereby, the Purchaser has relied solely upon its own investigation and the express representations and warranties of the Sellers set forth in <U>Article 3</U> of this Agreement (including the related portions
of the Schedules); and (ii) none of the Sellers, TangenX, TangenX Holding, or any other Person has made any representation or warranty as to the Sellers, TangenX, TangenX Holding or this Agreement, except as expressly set forth in <U>Article 3</U>
of this Agreement (including the related portions of the Schedules). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Confidentiality</B>. Each of the Sellers shall, and shall cause his or its Affiliates, and his, its or
such Affiliate&#146;s Representatives (collectively, the <B>&#147;Covered Persons&#148;</B>) to, treat and hold, as confidential and not disclose, any Confidential Information and any non-public, confidential or proprietary information concerning
the Purchaser and its Affiliates (together with any notes, analyses, compilations, studies, forecasts, interpretations or other documents that are derived from, contain, reflect or are based upon any such information, collectively, the
<B>&#147;Covered Information&#148;</B>), refrain from using any of the Covered Information (except to the extent that such Covered Information is disclosed in connection with such Seller providing services to the Purchaser or its Affiliates), and
deliver promptly to the Purchaser, at the request and option of the Purchaser, all tangible embodiments (and all copies) of the Covered Information which are in its or his possession or under its or his control. Notwithstanding the foregoing,
Covered Information shall not include information that is (i) generally available to the public other than as a result of a breach of this <U>Section 5.1</U> or other act or omission of a Covered Person, or (ii) lawfully received after the Closing
Date from a third party not known to a Covered Person to be under any obligation of confidentiality with respect to such information or fiduciary duty with respect to the secrecy of such information. In the event that a Covered Person is required in
any Proceeding, discovery, or any subpoena, civil investigative demand, or similar process to disclose any Covered Information, such Covered Person shall notify the Purchaser promptly of the requirement so that the Purchaser may seek an appropriate
protective order at its expense or waive compliance with the provisions of this <U>Section 5.1</U>.&nbsp;If, in the absence of a protective order or the receipt of a waiver hereunder, a Covered Person is, on the advice of counsel, required to
disclose any Covered Information in any Proceeding to any Governmental Body, such Covered Person may disclose such Covered&nbsp;Information to such Governmental Body; <U>provided</U>, that such Covered Person shall use commercially reasonable
efforts to obtain, at the request and expense of the Purchaser, an order or other assurance that confidential treatment shall be accorded to such portion of the Covered Information required to be disclosed as the Purchaser shall designate. Each
Seller shall hold in confidence the existence of and terms of this Agreement, except such Seller may disclose such information (a) to his or its Tax and financial advisors for purposes of complying with the Seller&#146;s Tax obligations or other
reporting obligations under Applicable Law arising out of the transactions contemplated hereby, (b) to his or its legal counsel and accountants, and (c) in the case of a Seller that is an entity, to its stockholders or bondholders and the
stockholders and bondholders of its Affiliates, provided that the disclosed information is limited to the results of the Seller&#146;s investment in TangenX and such other information as is required to be disclosed by the Seller pursuant to existing
agreements as of the date hereof, subject in each case to a duty or agreement of confidentiality. Nothing in this <U>Section 5.1</U> shall operate to prevent or inhibit any Covered Person from using or disclosing Covered Information to the extent
such Covered Person considers it necessary or desirable to do so for the purpose of exercising or enforcing any of his, her or its rights under <U>Section 2.5</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2&nbsp;&nbsp;&nbsp;&nbsp;Non-Competition/Non-Solicitation. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;No Seller shall, directly or indirectly, for a period of two (2) years after the Closing Date,
engage (whether as owner, employee, operator, manager, consultant or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
otherwise) anywhere in the world in any business that competes with the Business. Notwithstanding the foregoing, no Seller shall be prohibited by this <U>Section</U><U>&nbsp;</U><U>5.2(a)</U>
from acquiring or owning less than one percent (1%) of the outstanding voting power of any publicly traded company on a passive basis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;No Seller shall, nor shall he or it permit any of his or its Affiliates to, directly or indirectly,
for a period of two (2) years after the Closing Date, (i) solicit or attempt to induce any customer, supplier, agent or distributor of TangenX as of the Closing Date expected to materially adversely affect the Business, or (ii) contact, solicit or
approach for the purpose of offering employment to, or hire (whether as an employee, consultant, agent, independent contractor or otherwise), any employee employed by the Purchaser or any of its Affiliates (including TangenX) during the one-year
period preceding such contact, solicitation or approach (<U>provided</U>, that the foregoing clause shall not prohibit a Seller or its Affiliates from entering into discussions with, soliciting or employing any Person who responds to a general
solicitation not targeting any such employee).</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Each Seller, for itself or himself and on behalf
of its or his Affiliates, agrees that the scope of the restrictive provisions set forth in this <U>Section 5.2</U> are reasonable with respect to subject matter, time and scope and that the provisions contained in this <U>Section 5.2</U> are a
material inducement to the Purchaser&#146;s entering into this Agreement and but for the provisions contained in this <U>Section 5.2</U> the Purchaser would not have entered into this Agreement. In the event that any court determines that the
subject matter, duration or geographic scope, or all of the foregoing, is unreasonable and that such provision is to that extent unenforceable, the Purchaser and each Seller, for itself and on behalf of each of its Affiliates, agree that the
provision shall remain in full force and effect for the greatest time period and for the broadest subject matter and in the greatest area, as the case may be, that would not render it unenforceable. It is specifically understood and agreed that any
breach of the provisions of this <U>Section 5.2</U> by any Seller or any of its Affiliates will result in irreparable injury to the Purchaser, that the remedy at law alone will be an inadequate remedy for such breach and that, in addition to any
other remedy it may have, the Purchaser shall be entitled to enforce the specific performance of this <U>Section 5.2</U> by such Seller and its Affiliates through both temporary and permanent injunctive relief without the necessity of proving actual
damages and without posting a bond, but without limitation of their right to damages and any and all other remedies available to them, it being understood that injunctive relief is in addition to, and not in lieu of, such other remedies. For the
avoidance of doubt, the parties hereto acknowledge and agree that the restrictions set forth in this <U>Section 5.2</U> are in addition to any restrictions set forth in any employment agreement and/or any other Contract between the Purchaser or any
of its Affiliates (including TangenX), on the one hand, and any Seller, on the other hand. Each Seller acknowledges and agrees that he or it has received, or are receiving, substantial consideration in connection with the transactions contemplated
by this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this <U>Section 5.2</U>, with respect to Novasep, Affiliates
shall mean Novasep Holding SAS and all of its Affiliates other than (a) bona fide investors in Novasep Holding SAS or any such investor&#146;s portfolio companies or other investments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
and (b) any bona fide acquiror of Novasep Holding SAS or a material portion of its assets, which at the time of such acquisition, already conducts any business that competes with the Business as
long as such acquiror does not (during the period contemplated by <U>Section 5.2</U>) utilize personnel or resources of Novasep that were materially involved in the Business prior to the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Tax Matters</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Preparation of Tax Returns</U>. The Purchaser shall cause TangenX and TangenX Holding to prepare
and timely file all Tax Returns of TangenX and TangenX Holding for Pre-Closing Tax Periods that are due after the Closing Date (collectively, the &#147;<B>Purchaser Prepared Returns</B>&#148;).&nbsp;To the extent that a Purchaser Prepared Return
relates solely to a taxable period ending on or before the Closing Date, such Tax Return shall be prepared in accordance with existing procedures, practices, and accounting methods of TangenX, unless otherwise required by Applicable Law. Each
Purchaser Prepared Return that relates solely to a taxable period ending on or before the Closing Date shall be submitted to the Sellers for their review and comment at least twenty (20) days prior to the due date of such Purchaser Prepared Return
(taking into account extensions).&nbsp;The Purchaser shall consider any comments of the Sellers in good faith prior to filing such Purchaser Prepared Returns. No failure or delay in the Purchaser providing Purchaser Prepared Returns for the Sellers
to review shall reduce or otherwise affect the obligations or Liabilities of the Sellers pursuant to this Agreement. The Sellers shall pay to the Purchaser those Taxes shown on any Purchaser Prepared Return (and with respect to any Tax Returns for
any Straddle Period allocated to the Sellers in a manner consistent with <U>Section 5.3(b)</U>) no later than five (5) days before the Purchaser is required to file such Purchaser Prepared Returns with the applicable Governmental Body (taking into
account any extensions timely filed by TangenX), except to the extent the amount of any such Taxes was included as Indebtedness of TangenX, as finally determined. The Liabilities of TangenX identified on paragraphs (i), (ii), (iii) and (v) of
Appendix G shall be deemed for Tax purposes to have been paid by TangenX prior to the Closing and any and all Tax deductions for the full amount of such payments shall be attributed to the Pre-Closing Period to the extent permitted by Applicable
Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Apportionment of Taxes</U>. In the case of any Straddle Period, the amount of any Taxes
of TangenX (i) based on or measured by income or receipts, sales or use, employment, or withholding for the Pre-Closing Tax Period shall be determined based on an interim closing of the books as of the close of business on the Closing Date (and for
such purpose, the taxable period of any partnership or other pass-through entity in which TangenX holds a beneficial interest shall be deemed to terminate at such time) and (ii) the amount of other Taxes of TangenX for a Straddle Period for the
Pre-Closing Tax Period shall be deemed to be the amount of such Tax for the entire taxable period multiplied by a fraction, the numerator of which is the number of days in the Straddle Period prior to and including the Closing Date and the
denominator of which is the number of days in such Straddle Period.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Cooperation</U>. The
Purchaser, TangenX and the Sellers shall (and shall cause their respective Affiliates to: (i) assist in the preparation and timely filing of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Tax Return of TangenX, (ii) assist in any audit or other Proceedings with respect to Taxes or Tax Returns of TangenX, (iii) make available any information, records or other documents relating to
any Taxes or Tax Returns of TangenX, and (iv) provide any information necessary or reasonably requested to allow the Purchaser or TangenX to comply with any information reporting or withholding requirements contained in the Code or other Applicable
Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax Contests</U>. In the event TangenX or its Affiliates receives notice of any pending
or threatened Tax audits or assessments or other disputes concerning Taxes following the Closing Date with respect to which the Sellers may incur Liability hereunder (each, a &#147;<B>Tax Contest</B>&#148;), the Purchaser shall promptly notify the
Sellers of such matter in writing; <U>provided</U>, that no failure or delay of the Purchaser in providing such notice shall reduce or otherwise affect the obligations of the Sellers pursuant to this Agreement, except to the extent that the Sellers
are materially and adversely prejudiced as a result of such failure or delay. The Purchaser shall control, at the Sellers&#146; expense, any such Tax Contest; <U>provided</U>, that (x) the Sellers, at their own cost and expense, shall have the right
to participate in any such Tax Contest to the extent it relates to a Pre-Closing Tax Period and (y) the Purchaser shall not settle any such Tax Contest without the Sellers&#146; prior written consent, not to be unreasonably withheld, conditioned or
delayed. In the event of any conflict between <U>Article 6</U> and this <U>Section 5.3(d)</U>, the provisions of this <U>Section 5.3(d)</U> shall control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax Refunds</U>. The Sellers will be entitled to all refunds, credits for overpayment of Taxes or
reductions of Tax of TangenX for any Pre-Closing Tax Period. If the Purchaser or TangenX receives any refund, credit for overpayment of Taxes or benefit from any reduction in Tax to which TangenX is entitled pursuant to this
<U>Section</U><U>&nbsp;</U><U>5.3(e)</U>, the Purchaser or TangenX will promptly pay the amount of such refund (including interest received from a taxing authority thereon), credit or reduction in Tax to the Sellers, net of the amount of any Taxes
and out-of-pocket expenses that the Purchaser, TangenX or any Affiliate thereof incur with respect to such refund, credit or reduction in Taxes. In the event that any Tax refund or credit is subsequently determined by any taxing authority to be less
than the amount paid by the Purchaser, TangenX or any of their Affiliates to the Sellers pursuant to this <U>Section</U><U>&nbsp;</U><U>5.3(e)</U>, the Seller shall promptly return any such disallowed amount (plus any interest or penalties in
respect of such disallowed amount owed to any taxing authority) to the Purchaser. Notwithstanding the foregoing, nothing in this <U>Section</U><U>&nbsp;</U><U>5.3(e)</U> shall require that the Purchaser, TangenX or any of their Affiliates make any
payment with respect to any Tax refund (and such refund shall be for the benefit of the Purchaser) that is with respect to (i) any refund that is the result of the carrying back of any net operating loss or other Tax attribute or Tax credit incurred
in a taxable period (or portion thereof) beginning after the Closing Date, (ii) any refund resulting from the payment of Taxes made on or after the Closing Date to the extent the Sellers have not borne such Tax or otherwise have not indemnified the
Purchaser or TangenX for such Taxes or (iii) any refund that gives rise to a payment obligation by TangenX to any Person under Applicable Law or pursuant to a provision of a Contract or other agreement entered (or assumed) by TangenX on or prior to
the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer Taxes</U>. The Purchaser, on the one hand,
and the Sellers, on the other hand, shall each be responsible for fifty percent (50%) of all transfer, value-added, documentary, sales, excise, use, stamp, registration and other such Taxes, and all conveyance fees, recording charges and other fees
and charges (including any penalties and interest) incurred in connection with the consummation of the transactions contemplated by this Agreement (collectively, the &#147;<B>Transfer Taxes</B>&#148;).&nbsp;The Sellers shall file all necessary Tax
Returns and other documentation with respect to all such Transfer Taxes and, if required by Applicable Laws or to the extent reasonably requested, each of the Purchaser and TangenX shall, cooperate in the preparation and filing and join in the
execution of any such Tax Returns and other documentation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Post-Closing
Actions</U>.&nbsp;The Purchaser covenants that it will not cause or permit TangenX or TangenX Holding to (i) take any action between the Closing and 11:59 p.m. EST on the Closing Date (other than actions consistent with past practices and that are
taken in connection with the normal day-to-day operations of such entities) that could reasonably be expected to give rise to any Tax liability or reduce any Tax asset that otherwise would be taken into account in determining any Tax to be paid by
the Sellers, TangenX or TangenX Holding or (ii) make or change any Tax election, adopt or change any accounting method or amend any Tax Return, in each case, in respect of any Pre-Closing Tax Period that could reasonably be expected to result in any
increased Tax liability or reduction of any Tax asset for the Sellers, TangenX or TangenX Holding without the Sellers&#146; prior written consent (not to be unreasonably withheld conditioned or delayed). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax Adjustment Amount</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;As soon as practicable, and in no event later than forty-five (45) days, following the Closing Date,
Novasep shall deliver to the Purchaser a calculation of the final tax adjustment amount relating to the Reorganization (the &#147;<B>Tax Adjustment Amount</B>&#148;), prepared in good faith in accordance with this <U>Section 5.3(h)</U>, taking into
account all appropriate state, federal and local Tax implications, along with reasonable supporting detail to evidence the calculation of such amount. The Tax Adjustment Amount shall be calculated in the same manner as, and using the same
assumptions and methodologies, as the Estimated Tax Adjustment Amount as set forth on <B><U>Appendix I</U></B><B> </B>and, in all cases, in accordance with Applicable Law. The Purchaser shall have a period of thirty (30) days to review and provide
notice to Novasep if the Purchaser objects to any portion of Novasep&#146;s calculation.&nbsp;During this period, Novasep shall provide the Purchaser with any other information reasonably requested by the Purchaser in connection with the
Purchaser&#146;s review of such calculations. Any such information provided by Novasep to the Purchaser or its representatives in connection with this <U>Section 5.3(h)</U> shall be held strictly confidential, and such information shall only be
disclosed to those representatives of the Purchaser necessary to accomplish the purposes of this <U>Section 5.3(h)</U>. Any disputes with respect to the calculation of the Tax Adjustment Amount that cannot be resolved through negotiations between
the Purchaser and Novasep pursuant to this <U>Section </U><U>5.3(h)</U> shall be taken to the Accounting Referee and resolved in the same manner as disputed matters are to be resolved pursuant to <U>Section 2.5(d)</U>.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The Estimated Tax Adjustment Amount shall reduce the
amount paid to Novasep at the Closing in accordance with <B><U>Appendix C</U></B>. If the Tax Adjustment Amount, as finally determined pursuant to this <U>Section 5.3(h)</U>, exceeds the Estimated Tax Adjustment Amount, such excess shall be paid by
Novasep, and such payment shall be made in full no later than five (5) Business Days prior to the date the Tax Return on which the Tax related to the additional Tax Adjustment Amount is required to be reported is due. If the Estimated Tax Adjustment
Amount exceeds the Tax Adjustment Amount as finally determined pursuant to this <U>Section 5.3(h)</U>, such excess shall be reimbursed to Novasep and such payment shall be made by the Purchaser promptly (and in any event within five (5) Business
Days) after the filing of the Tax Return on which the Tax related to the Tax Adjustment Amount is required to be reported.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Release. </B>Each Seller, on behalf of itself or himself and each of its or his Affiliates,
beneficiaries, estate, successors and assigns (each, a &#147;<B>Releasor</B>&#148;), hereby irrevocably and unconditionally releases the Purchaser, its Affiliates and any of their Representatives, successors and assigns (including TangenX and
TangenX Holding) (collectively, the &#147;<B>Releasees</B>&#148;) from any and all charges, complaints, claims, Liabilities, obligations, promises, agreements, controversies, damages or causes of action, suits, rights, demands, costs, losses, debts
and expenses (including attorneys&#146; fees and costs incurred) of any nature whatsoever, known or unknown, suspected or unsuspected, existing or prospective, relating to TangenX and TangenX Holding, their respective assets and properties or the
Business (collectively, &#147;<B>Claims</B>&#148;); <U>provided</U>, <U>however</U>, that the foregoing release shall not cover:&nbsp;(i) Claims arising from rights of any Releasor under this Agreement, any Ancillary Document or any other agreement
entered into by such Releasor with a Releasee in connection with the Closing, (ii) any right to indemnification under Applicable Law or the organizational documents of TangenX, or (iii) with regard to Connors, who is an employee of TangenX, any
Claims for accrued and unpaid compensation or benefits or other matters relating to his status as a service provider to TangenX (but specifically excluding for purposes of this clause (iii) any compensatory equity compensation benefit or award)
(collectively, &#147;<B>Excluded Claims</B>&#148;).&nbsp;Such Releasor expressly acknowledges that the release contained herein applies to all Claims other than Excluded Claims, regardless of whether such Claims are known or unknown, suspected or
unsuspected, existing or prospective, and include Claims which, if known by the Releasor, might materially affect its decision to enter into this Agreement. Such Releasor has considered and taken into account the possible existence of such Claims in
determining whether to execute and deliver this Agreement. Such Releasor has the legal capacity to execute and deliver this Agreement, and perform any obligations under this <U>Section 5.4</U>.&nbsp;Such Releasor irrevocably and unconditionally
covenants and agrees not to assert any suit, demand, litigation, lawsuit, action or claim with respect to any Claim; <U>provided</U> that the foregoing covenant shall not apply to any Excluded Claim. Such Releasor confirms and agrees that it or he
(i) has had a reasonable time and opportunity to consult with the its financial, legal, Tax and other advisors, if desired, before signing this Agreement, and (ii) has not relied on any representation or statement not set forth in this Agreement
made by any Representative of the Purchaser, TangenX or any other Person with regard to the subject matter, basis or effect of this Agreement or otherwise. Such Releasor acknowledges that this <U>Section 5.4</U> is a material inducement for the
Purchaser to enter into this Agreement and effect the transactions contemplated hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>D&amp;O Insurance Policy. </B>On or<B> </B>prior to Closing
Date, TangenX will purchase and fully pay the premium for (or include the premium payable as a Transaction Cost), directors&#146; and officers&#146; fiduciary Liability run-off insurance for the directors and officers of both TangenX and TangenX
Holding (and errors and omissions insurance, but only to the extent that as of the date hereof TangenX and TangenX Holding have such coverage), each of which shall by its terms survive the Closing and provide run-off coverage for six years following
the Closing Date for TangenX and TangenX Holding and the directors and officers of TangenX and TangenX Holding serving TangenX and TangenX Holding immediately prior to the Closing Date who, prior to the Closing Date, were covered by directors&#146;
and officers&#146; liability insurance policies in which TangenX and TangenX Holding are named insureds or covered by such policies with respect to matters arising at or prior to the Closing Date. The terms of such policy are identified on Schedule
5.5 to this Agreement. TangenX shall cause such insurance to be bound not later than the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Statements. </B>Following the Closing Date, upon the reasonable request of the Purchaser in
connection with the preparation of the financial statements of TangenX and TangenX Holding to be included in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, including as required by Rule
3-05 of Regulation S-X, or any NASDAQ Global Market listing requirements (collectively, the &#147;<B>Applicable Securities Laws</B>&#148;), each Seller shall provide information requested by the Purchaser and use its or his commercially reasonable
efforts to assist in the preparation of (i) an audit of the financial information of TangenX and TangenX Holding for the periods required pursuant to the Applicable Securities Laws, in each case assuming the consummation of the Closing (the
&#147;<B>Audited Financial Statements</B>&#148;), and (ii) the pro forma financial information relating to the Purchaser&#146;s acquisition of all of the equity of TangenX and TangenX Holding, as required by the Applicable Securities Laws, in each
case assuming the consummation of the Closing (together with the Audited Financial Statements, the &#147;<B>Required Financial Information</B>&#148;).&nbsp;In connection with the foregoing, each Seller will generally cooperate with the
Purchaser&#146;s reasonable requests in order to facilitate preparation of the Required Financial Information. Any out-of-pocket, documented and reasonable costs incurred with the Audit Accountants for the preparation of the Required Financial
Information shall be paid by the Purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7&nbsp;&nbsp;&nbsp;&nbsp;Benefit Plans. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Assumption of Liabilities</U>. Neither the Purchaser nor any of its Affiliates (including TangenX
and TangenX Holding) shall assume any Liability with respect to any Benefit Plan or other employee benefit plan of any kind or nature maintained by Novasep, LLC or any of its Affiliates for any of the current or former employees, directors or other
service providers who perform services for TangenX (collectively, the &#147;<B>TangenX Employees</B>&#148;), other than the Benefit Plans maintained solely by TangenX. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Defined Contribution Plans</U>.&nbsp;On the Closing Date, Novasep shall make, or cause to be
made, all employee and required employer contributions with respect to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
TangenX Employees&#146; employment service to the Novasep, LLC 401(k) plan (the &#147;<B><U>Novasep 401(k) Plan</U></B>&#148;) and shall cause the accounts of all TangenX Employees under the
Novasep 401(k) Plan to become fully vested as of the Closing Date.&nbsp;TangenX Employees with outstanding participant loan balances under the Novasep 401(k) Plan shall be permitted to roll over their plan loans to the Purchaser&#146;s 401(k) plan
after the Closing as part of any qualifying rollover distribution.&nbsp;Novasep shall not place any participant loan in default under the Novasep 401(k) Plan, <U>provided</U> that each TangenX Employee apply for a distribution and rollover of his or
her 401(k) plan in a timely manner so that rollovers can be made prior to the end of the grace period for the repayment of the loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Stock Repurchase Price Adjustment for Mark Perreault. </B><B><U>Appendix G</U></B> contains an accrued
liability in respect of a stock repurchase price adjustment of $509,479.76 payable to Mark Perreault pursuant to the terms of the Bonus Letter Agreement, dated October 23, 2016, by and between Mark Perreault and TangenX (the &#147;<U>Perreault Bonus
Agreement</U>&#148;).&nbsp;The Purchaser shall cause TangenX to pay such $509,479.76 to Mark Perreault following the Closing pursuant to the terms of the Perreault Bonus Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Reliance. </B>All representations, warranties, covenants, and agreements of the Sellers and the Purchaser
made in this Agreement, in the Schedules delivered to the Purchaser, and in any Ancillary Document (i) are material and shall be deemed to have been relied upon by the party or parties to whom they are made, and shall survive the Closing in
accordance with <U>Section 6.4</U> regardless of any investigation on the part of such party or its Representatives, with each party reserving all of its rights hereunder in connection with any breach or alleged breach, and (ii) shall bind the
parties&#146; successors and assigns (including any successor to the Purchaser or any Seller that is an entity by way of acquisition, merger or otherwise), whether so expressed or not, and, except as otherwise provided in this Agreement, all such
representations, warranties, covenants and agreements shall inure to the benefit of the parties and their respective successors and assigns, whether so expressed or not. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2&nbsp;&nbsp;&nbsp;&nbsp;Indemnification by the Sellers.</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each Seller, on a several and not joint basis, up to his or its Pro Rata Share of the applicable
Loss and subject to <U>Section 6.2(b)</U>, hereby covenant and agree to indemnify and hold the Purchaser, its Affiliates (including TangenX and TangenX Holding), and their respective directors, officers, employees, stockholders and agents, and each
of their successors and permitted assigns (each, a &#147;<B>Purchaser Indemnified Party</B>&#148;), harmless from, against and in respect of any and all Losses that any Purchaser Indemnified Party may at any time, directly or indirectly, suffer,
sustain, incur or become subject to, arising out of, based upon, or resulting from or on account of each of the following: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The breach or falsity of any representation or
warranty made by any Seller in this Agreement or any Ancillary Document; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The breach or
non-fulfillment of any covenant or agreement made by any Seller in this Agreement or any Ancillary Document; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The allocation of the Purchase Price among the Sellers and any other Persons sharing, or claiming
to share, directly or indirectly as payees of the Purchase Price, including under the organizational documents of TangenX or any other Contract, and including any inaccuracy in <B><U>Appendix C</U></B>; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;Any claim for a breach of the fiduciary duty of any director or stockholder of TangenX or TangenX
Holding at or prior to the Closing; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;Any Indemnified Taxes; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;Any Closing Transaction Expenses; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;Any Transaction Costs not included in the Final Transaction Costs; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;Any Indebtedness not included in the Final Indebtedness; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;Any claim by or on behalf of Mark Perreault with respect to the Repurchased Shares; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;Any claim for any pre-Closing Liability of TangenX Holding (including for, but without duplication
of, any Indemnified Taxes); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi)&nbsp;&nbsp;&nbsp;&nbsp;Any claim for any Liability of Novasep or Novasep, LLC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the provisions in <U>Section 6.2(a)</U>, the parties acknowledge and agree that
Connors shall not indemnify or hold any Purchaser Indemnified Party harmless from, against and in respect of any and all Losses that any Purchaser Indemnified Party may at any time, directly or indirectly, suffer, sustain, incur or become subject
to, arising out of, based upon, or resulting from or on account of any of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The
breach or falsity of any representation or warranty made by Novasep in this Agreement or any Ancillary Document relating to Novasep, TangenX Holding, Novasep Americas, or Novasep, LLC; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The breach or non-fulfillment of any covenant or agreement made by Novasep in this Agreement or any
Ancillary Document; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Any claim for a breach of the fiduciary duty of any director or
stockholder of TangenX at or prior to the Closing, unless such claim was brought by Connors or made in respect of any action or inaction by Connors; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;Any claim for a breach of the fiduciary duty of any
director or stockholder of TangenX Holding at or prior to the Closing; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) &nbsp;&nbsp;&nbsp;&nbsp;Any claim by or on
behalf of Mark Perreault with respect to the Repurchased Shares; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;Any claim for any pre-Closing
Liability of TangenX Holding (including for, but without duplication of, any Indemnified Taxes in respect of TangenX Holding); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;Any claim for any Liability of Novasep or Novasep, LLC; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;Any Transaction Costs or Closing Transaction Expenses not included in the Final Transaction Costs, except for any
bonuses, retention obligations or similar amounts payable by or due from TangenX that are triggered solely by the transactions contemplated hereby to the extent not accrued for in the calculation of Estimated Working Capital, but not except for any
Transaction Payroll Taxes and/or any unemployment insurance contributions with respect to any such bonuses, retention obligations or similar amounts payable by or due from TangenX; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;Any adjustment to the Purchase Price pursuant to the terms of <U>Section 2.5</U>, to the extent such
adjustment relates to or is affected by the amount of Transaction Costs, except for any bonuses, retention obligations or similar amounts payable by or due from TangenX that are triggered solely by the transactions contemplated hereby; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;any adjustment to the Purchase Price pursuant to the terms of <U>Section 5.3(h)</U>; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi)&nbsp;&nbsp;&nbsp;any Taxes: (A) imposed on TangenX Holding or TangenX resulting from the sale of Novasep, LLC to Novasep
Americas or the distribution of the stock of TangenX to TangenX Holding; (B) of any member (other than TangenX) of an affiliated, consolidated, combined or unitary group of which TangenX Holding (or any predecessor thereof) is or was a member on or
prior to the Closing Date, including pursuant to Treasury Regulations Section 1.1502-6 or any analogous or similar state, local or non-U.S. law; or (C) of any Person imposed on TangenX Holding as a transferee or successor, by Contract,
indemnification agreement or otherwise, or pursuant to any law, which Taxes relate to an event, agreement or transaction occurring on or before the Closing Date. Notwithstanding the foregoing, Connors shall solely be liable for any Taxes imposed on
him relating to the sale of the Connors-Owned Stock pursuant to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">With respect to any Losses that any Purchaser Indemnified
Party suffers, sustains, incurs or becomes subject to, that are subject to this Section 6.2(b), Novasep&#146;s Pro Rata Share shall be 100%.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Indemnification by the Purchaser. </B>The Purchaser hereby
covenants and agrees to defend, indemnify and hold the Sellers, their directors, officers, employees, Affiliates, shareholders and agents, and each of their successors and assigns (each a &#147;<B>Seller Indemnified Party</B>&#148;, and collectively
with the Purchaser Indemnified Parties, the &#147;<B>Indemnified Parties</B>&#148;), harmless from, against and in respect of any and all Losses that any Seller Indemnified Party may at any time, directly or indirectly, suffer, sustain, incur or
become subject to, arising out of, based upon, or resulting from or on account of each or all of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The breach or falsity of any representation or warranty made by the Purchaser in this Agreement or
any Ancillary Document; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The breach or non-fulfillment of any covenant or agreement made by the
Purchaser in this Agreement or any Ancillary Document; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Non-payment by the Purchaser of the
Closing Cash Consideration set forth on <B><U>Appendix C</U></B> pursuant to <U>Section 2.3</U> of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4&nbsp;&nbsp;&nbsp;&nbsp;Survival Periods. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival Period for Representations</U>. All representations and warranties contained in this
Agreement shall survive for a twelve (12) month period following Closing (during which written notice of a claim will preserve such claim in <U>Section</U><U>&nbsp;</U><U>6.4(c))</U> (the &#147;<B>Escrow Release Date</B>&#148;); <U>provided</U>,
<U>however</U>, that (i) the representations and warranties made pursuant to <U>Section 3.7</U> (Tax Matters) shall survive until thirty (30) days following the expiration of the applicable statutory period of limitation (including all periods of
extension, whether automatic or permissive) (during which written notice of a claim will preserve such claim in <U>Section</U><U>&nbsp;</U><U>6.4(c))</U>; (ii) the representations and warranties made pursuant to <U>Section</U><U>&nbsp;</U><U>3.1</U>
(Organization), <U>Section</U><U>&nbsp;</U><U>3.2</U> (Capitalization), <U>Section</U><U>&nbsp;</U><U>3.3</U> (Due Authorization), <U>Section</U><U>&nbsp;</U><U>3.18</U> (Brokers) and <U>Section</U><U>&nbsp;</U><U>3.19</U> (Relationship with Related
Persons) shall survive until thirty (30) days following the latest expiring statute of limitations applicable to the rights of any Person to bring any claim with respect to such matters (during which written notice of a claim will preserve such
claim in <U>Section</U><U>&nbsp;</U><U>6.4(c))</U>; and (iii) the representations and warranties made pursuant to <U>Section</U><U>&nbsp;</U><U>4.1</U> (Organization), <U>Section</U><U>&nbsp;</U><U>4.2</U> (Due Authorization), and
<U>Section</U><U>&nbsp;</U><U>4.6</U> (Brokers) shall survive until thirty (30) days following the latest expiring statute of limitations applicable to the rights of any Person to bring any claim with respect to such matters (during which written
notice of a claim will preserve such claim in <U>Section</U><U>&nbsp;</U><U>6.4(c))</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival Period for Covenants</U>. The covenants and other agreements contained in this Agreement
shall survive the Closing indefinitely or for the period contemplated by their respective terms, and the period during which a claim for indemnification may be asserted in connection therewith shall survive the Closing until thirty (30) days
following the latest expiring statute of limitations applicable to the rights of any Person to bring any claim with respect to such matters (during which written notice of a claim will preserve such claim in
<U>Section</U><U>&nbsp;</U><U>6.4(c))</U>.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification Claims</U>. Notwithstanding the
foregoing in this <U>Section</U><U>&nbsp;</U><U>6.4</U>, any claims asserted in good faith with reasonable specificity (to the extent known at such time) and in writing by notice from the non-breaching party(ies) within the time periods set forth in
this <U>Section 6.4</U> shall not thereafter be barred by the expiration of such survival period and such claims shall survive until finally and fully resolved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.5&nbsp;&nbsp;&nbsp;&nbsp;Limits on Indemnification. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Sellers (calculated in the aggregate), on the one hand, or the Purchaser, on the other hand,
shall not be obligated to provide indemnification under <U>Section</U><U>&nbsp;</U><U>6.2(a)(i)</U> as modified by <U>Section 6.2(b)</U> (other than claims with respect to <U>Section</U><U>&nbsp;</U><U>3.1</U> (Organization),
<U>Section</U><U>&nbsp;</U><U>3.2</U> (Capitalization), <U>Section 3.3</U> (Due Authorization), <U>Section 3.7</U> (Tax Matters), <U>Section 3.18</U> (Brokers) and <U>Section 3.19</U> (Relationship with Related Persons) (collectively, the
&#147;<B>Seller Fundamental Reps</B>&#148;), for which this <U>Section</U><U>&nbsp;</U><U>6.5(a)</U> shall not apply) and <U>Section</U><U>&nbsp;</U><U>6.3(a)</U> (other than claims with respect to <U>Section 4.1</U> (Organization), <U>Section
4.2</U> (Due Authorization), and <U>Section 4.6</U> (Brokers), for which this <U>Section 6.5(a)</U> shall not apply), as applicable, until the total of all Losses with respect to such matters exceeds &#128;370,000, which constitutes One Percent
(1.0%) of the Base Price, and then only for the amount by such Losses exceed $200,000. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;No
Seller shall have any Liability beyond his or its Pro Rata Share of 7.5% of the Base Price (i.e., for Novasep 5.98% and for Connors 1.52%, unless <U>Section 6.2(b)</U> applies, in which case Novasep&#146;s Pro Rata Share shall be 7.5% of the Base
Price) for any Losses incurred by the Purchaser Indemnified Parties pursuant to <U>Section 6.5(a)</U> (other than the Seller Fundamental Reps, for which this <U>Section 6.5(b)</U> shall not apply) in the aggregate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;No Seller shall be required to provide indemnification under this <U>Article 6</U> in an aggregate
amount in excess of the portion of the Pro Rata Share of the Purchase Price (including any Escrow Funds).&nbsp;The Purchaser shall not be required to provide indemnification under this <U>Article 6</U> in an aggregate amount in excess of the
Purchase Price. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The Indemnified Parties&#146; right to indemnification pursuant to this
<U>Article 6</U> on account of any Losses will be reduced by all insurance or other third party indemnification or contribution proceeds actually received by the Indemnified Parties in respect of those Losses. The Indemnified Parties shall remit to
the party from which such Indemnified Party is seeking indemnification under this <U>Article 6</U> (the &#147;<B>Indemnifying Party</B>&#148;), for the benefit of such other party, any such insurance or other third party proceeds that are paid to
the Indemnified Parties with respect to Losses for which the Indemnified Parties have been previously indemnified pursuant to this <U>Article 6</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Purchaser Indemnified Parties&#146; right to indemnification will be satisfied first from the
Escrow Fund, subject to the terms of the Escrow Agreement; provided, however, notwithstanding the forgoing, that the Purchaser Indemnified Parties shall have the right to satisfy any amounts due to the Purchaser Indemnified Parties&#146; under
<U>Section 5.3(h)</U> from either Novasep or the Escrow Fund. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the other provisions of this
<U>Section 6.5</U> or <U>Article 6</U>, the limitations set forth in this <U>Section 6.5</U> and <U>Article 6</U> shall not apply in the case of fraud, intentional misrepresentation or willful misconduct of a party hereto; provided, however, that
this <U>Section 6.5(f)</U> shall have no effect on <U>Section 6.2(b)</U>, such that any fraud, intentional misrepresentation or willful misconduct of Novasep shall not affect the limitations with respect to Connors and any fraud, intentional
misrepresentation or willful misconduct of Connors shall not affect the limitations with respect to Novasep.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of the parties&#146; indemnification obligations under this
<U>Article</U><U>&nbsp;</U><U>6</U>, all of the representations and warranties set forth in this Agreement that are qualified as to &#147;material,&#148; &#147;materiality,&#148; &#147;material respects,&#148; or words of similar import or effect
shall be deemed to have been made without any such qualification for purposes of determining the amount of Losses resulting from, arising out of or relating to any such breach of representation or warranty (other than &#147;material adverse
effect&#148; in <U>Section</U><U>&nbsp;</U><U>3.10)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;In no event shall any Indemnifying
Party be liable to any Indemnified Party for any punitive, consequential, special or indirect damages (other than incidental), including loss of future revenue or income, loss of business reputation or opportunity relating to the breach or alleged
breach of this Agreement or any Ancillary Documents, or any damages based on any type of multiple. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.6&nbsp;&nbsp;&nbsp;&nbsp;Notice
of Loss of Third Party Claims. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;An Indemnified Party shall give the Indemnifying Party
prompt written notice of any matter which an Indemnified Party has determined gives rise or could reasonably be expected to give rise to a right of indemnification under this Agreement stating the amount of the Loss, if known, and method of
computation thereof (if known), and containing a reference to the provisions of this Agreement in respect of which such right of indemnification is claimed or arises; <U>provided</U>, that no failure or delay of the Indemnified Party in providing
such notice shall reduce or otherwise affect the obligations of the Indemnifying Party pursuant to this Agreement, except to the extent that such Indemnifying Party is materially and adversely prejudiced as a result of such failure or delay. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If an Indemnified Party shall receive notice of any Proceeding, action, audit, claim, demand or
assessment against it from a third party (each, a &#147;<B>Third-Party Claim</B>&#148;), which gives rise or would reasonably be expected to give rise to a claim for Loss under this <U>Article 6</U>, the Indemnified Party shall give the Indemnifying
Party prompt written notice of such Third-Party Claim together with copies of all notices and documents served on or received by the Indemnified Party; <U>provided</U>, that no failure or delay of the Indemnified Party in providing such notice or
documents shall reduce or otherwise affect the obligations of the Indemnifying Party pursuant to this Agreement, except to the extent that such Indemnifying Party is materially and adversely prejudiced as a result of such failure or delay. The
Indemnifying Party shall be entitled to assume and control the defense of such Third-Party Claim at its expense and through counsel reasonably acceptable to the Indemnified Party if it gives written notice of its intention to do so to the
Indemnified Party within ten (10) Business Days of the receipt of such notice </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
from the Indemnified Party (but in all cases within such time as is reasonable to permit the Indemnified Party to adequately respond to any such claim in the event that the Indemnifying Party
will not assume the defense thereof), which notice shall state and agree that the Indemnifying Party would be liable under the provisions hereof for indemnity in the amount claimed by such third party if such claims by such third party (subject to
any applicable limitations set forth in <U>Section 6.5</U>) are valid and that such Indemnifying Party intends to defend against such Third Party Claims in good faith, and to assume and conduct the defense of such claim with counsel selected by the
Indemnifying Party, at the Indemnifying Party&#146;s sole cost and expense; <U>provided</U>, <U>however</U>, that the Indemnifying Party shall not settle, compromise or otherwise resolve any Third-Party Claim without the Indemnified Party&#146;s
prior written consent (not to be unreasonably withheld, conditioned or delayed) to the extent such settlement, compromise or other resolution could have an adverse impact on the Indemnified Party; <U>provided</U>, <U>further</U>, that the
Indemnifying Party shall not be permitted to assume the defense without the consent of the Indemnified Party if the Third-Party Claim seeks monetary damages in excess of the Indemnifying Party&#146;s or Indemnifying Parties&#146; then-remaining
maximum Liability hereunder (taking into account the limitations set forth in <U>Section 6.5</U>), seeks an order, injunction or other equitable relief or relief for other than money damages against the Indemnified Party, or where the Indemnified
Party has determined in good faith that the Third-Party Claim could have a material impact on its or its Affiliates&#146; reputation or its or its Affiliates&#146; intellectual property or products. If the Indemnifying Party elects to undertake any
such defense against a Third-Party Claim, the Indemnified Party may participate in such defense at its own expense. If the parties to the action or Proceeding include both the Indemnifying Party and the Indemnified Party and the Indemnified Party
has been advised in writing by legal counsel that it has available to it one or more defenses or counterclaims which are inconsistent with one or more defenses or counterclaims which may be alleged by the Indemnifying Party, as a result of which
representation of both parties by the same counsel would be inappropriate under applicable standards of professional conduct, the reasonable expense of separate counsel for such Indemnified Party shall be paid by the Indemnifying Party;
<U>provided</U>, that such Indemnifying Party shall be obligated to pay for only one counsel for the Indemnified Party in any jurisdiction. Further, if the Indemnifying Party does not assume control of the defense in accordance with this <U>Section
6.6(b)</U> or a diligent good faith defense is not being or ceases to be conducted by the Indemnifying Party, the Indemnified Party may undertake the defense of (with counsel selected by such Indemnified Party) and shall have the right to compromise
or settle such Third Party Claim; <U>provided</U>, <U>however</U>, that if the Indemnifying Party has not consented (such consent not to be unreasonably withheld, conditioned or delayed) to any compromise or settlement of such claims, then the
amount of such compromise or settlement shall not be dispositive of the amount of Losses the Indemnified Party may recover pursuant to the indemnity provided in this <U>Article 6</U>.&nbsp;Except with the prior written consent of the Indemnified
Party (such consent not to be unreasonably withheld, conditioned or delayed), no Indemnifying Party, in the defense of any such claim, will consent to the entry of any judgment or enter into any settlement that (i)&nbsp;includes any remedy other
than a cash payment, which is fully satisfied by the Indemnifying Party, or (ii)&nbsp;does not include as an unconditional term thereof the giving by each claimant or plaintiff to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Indemnified Party of a release from all Liability with respect to such claim. If the Indemnifying Party has properly assumed the defense of a Third Party Claim pursuant to this <U>Article 6</U>,
the Indemnified Party shall reasonably cooperate with the Indemnifying Party in such defense and make available to the Indemnifying Party, at the Indemnifying Party&#146;s expense, all witnesses, pertinent records, materials and information in the
Indemnified Party&#146;s possession or under the Indemnified Party&#146;s control relating thereto (or in the possession or control of any of its Affiliates or its or their Representatives) as is reasonably requested by the Indemnifying Party or its
counsel. If the Indemnifying Party has not properly assumed the defense of a Third Party Claim pursuant to this <U>Article 6</U>, the Indemnifying Parties shall reasonably cooperate with the Indemnified Party in its defense and make available to the
Indemnified Party all witnesses, pertinent records, materials and information in the Indemnifying Party&#146;s possession or under the Indemnifying Party&#146;s control relating thereto (or in the possession or control of any of its Affiliates or
its or their Representatives) as is reasonably requested by the Indemnified Party or its counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Remedies</B>.&nbsp;Each of the parties hereto acknowledges and agrees that following the Closing, except
with respect to matters covered by <U>Section 2.5</U>, the indemnification provisions in <U>Article 6</U> shall be the sole and exclusive remedies of the parties hereto for any breach of the representations and warranties contained in this Agreement
and for any failure to perform and comply with any covenant or agreement in this Agreement. Notwithstanding the foregoing, the provisions of this <U>Article 6</U> will not prevent or limit a cause of action (i) under <U>Section 5.2</U> to obtain an
injunction or injunctions to prevent breaches of covenants in this Agreement or to seek other remedies for breaches of covenants in this Agreement as contemplated by <U>Section 7.16</U>, (ii)&nbsp;under <U>Section 2.5</U> to enforce any decision or
determination of the Accounting Referee, or (iii)&nbsp;for fraud, intentional misrepresentation or willful misconduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Treatment of Indemnification Payments</B>.&nbsp;All indemnification and other payments under this
<U>Article 6</U> shall, to the extent permitted by Applicable Law, be treated for all income Tax purposes as adjustments to the Purchase Price. None of the Purchaser, TangenX. TangenX Holding, the Sellers shall take any position on any Tax Return,
or before any Governmental Body, that is inconsistent with such treatment unless otherwise required by any Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Escrow</B>.&nbsp;Subject to the terms and conditions of this Agreement and the Escrow Agreement, on the
Escrow Release Date, the parties shall execute and deliver to the Escrow Agent a Joint Written Direction (as defined in the Escrow Agreement) directing&nbsp;the Escrow Agent to release the Escrow Amount, less, without duplication, (i) the aggregate
amount of any indemnification obligations of the Sellers paid out of the Escrow Account or payments made to the Purchaser pursuant to <U>Section 2.5(c)</U> from the Escrow Account, (ii) the aggregate amount of any indemnification obligations of the
Sellers that have been resolved but remain unpaid, (iii) the aggregate amount of any indemnification claims by the Purchaser Indemnified Parties, and of which the Sellers have been notified in a Claim Notice (as defined in the Escrow Agreement) on
or prior to the Escrow Release Date, and (iv) such other amount, if any, as may be agreed in writing between the Sellers and Purchaser, (if such amount is positive) to the Sellers from the Escrow Account based on their Pro Rata Share. Any portion of
the Escrow Amount held by the Escrow Agent following the Escrow Release Date shall be released in accordance with the terms of this Agreement and the Escrow Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Denomination of Payments. </B>Any payment made after the Closing Date, including any adjustments to the
Purchase Price pursuant to <U>Section 2.5</U> and any claims pursuant to <U>Section 6.5</U>, shall be made in United States Dollars. Notwithstanding the forgoing, any claim made against the Escrow Fund shall be made in Euros, with the value of such
claim determined by reference to the relevant exchange rate as published in the Eastern Edition of The Wall Street Journal on the date such claim is made or, if such day is not a Business Day, on the Business Day immediately preceding such date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Number and Gender. </B>Unless the context otherwise requires, words importing the singular number
shall include the plural and vice versa and words importing the use of any gender shall include all genders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Public Announcements. </B>Unless required by Applicable Law or applicable stock exchange regulation, the
timing and content of all public announcements relating to the execution of this Agreement and the consummation of the transactions contemplated hereby shall be approved by both the Purchaser and the Sellers prior to the release of such public
announcements; <U>provided</U>, that to the extent practicable, each party agrees to consult with the Purchaser and the Sellers prior to making any public announcement required by Applicable Law or applicable stock exchange regulation regarding the
content of such disclosure. Unless otherwise agreed by the Sellers and the Purchaser, the parties agree that the press release attached hereto as <B><U>Appendix E</U></B> shall be issued within two (2) Business Days following the Closing Date.
Notwithstanding the foregoing, Novasep and its Affiliates shall be permitted, without the prior written consent of the Purchaser, to disclose the Purchase Price to its and their respective shareholders and bondholders if permissible under <U>Section
5.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Cooperation. </B>The parties agree that, at any time and from time to time, on and after
the Closing Date, upon the reasonable request of the other party(ies), they will do or cause to be done all such further acts and things and execute, acknowledge and deliver, or cause to be executed, acknowledged and delivered any and all papers,
documents, instruments, agreements, assignments, transfers, assurances and conveyances as may be necessary or desirable to carry out and give effect to the provisions and intent of this Agreement and the Ancillary Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notices. </B>All notices, demands and other communications provided for hereunder shall be in writing and
shall be given (i) by personal delivery, (ii) via facsimile transmission (receipt telephonically confirmed), (iii) by nationally recognized overnight courier (prepaid), or (iv) by certified or registered first class mail, postage prepaid, return
receipt requested, sent to each party, at its and its Representative&#146;s address as set forth below or at such other address or in such other manner as may be designated by such party or the respective Representative in a written notice to each
of the other parties. All such notices, demands and communications shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be effective (i) when personally delivered, (ii) one (1) Business Day after delivery to the overnight courier, (iii) upon telephone confirmation of facsimile transmission, or (iv) upon receipt
after dispatch by mail to the party to whom the same is so given or made: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">If&nbsp;to&nbsp;Novasep:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOVASEP PROCESS SAS</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">81 boulevard de la
Moselle</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">54340 Pompey</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">France</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile: 011-33-3-8349-7130</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Mr. Philippe Stoll,
President</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>With a copy to (but shall not constitute notice to Novasep):</I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOVASEP HOLDING SAS</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">39 rue St-Jean de Dieu</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lyon 69007</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">France</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile: 011-33-4-3728-2060</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Mr. Pierre-Louis Mikus, Chief Legal Officer</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fox Rothschild LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2000 Market Street, 20<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philadelphia, PA 19103</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile: 215-345-7507</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Peter J. Tucci,
Esquire</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">If&nbsp;to&nbsp;John&nbsp;Connors:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Mr. John Connors</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5 Municipal Drive</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Shrewsbury, MA 01545</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>With a copy to (but shall not constitute notice to Connors):</I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mirick, O&#146;Connell, DeMallie &amp; Lougee LLP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 Front Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Worcester, MA 01608</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile: (508) 463-1388</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Andrew A. Croxford,
Esq.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">If&nbsp;to&nbsp;the&nbsp;Purchaser:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Repligen Corporation</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">41 Seyon Street, Building #1, Suite 100</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham, MA 02453</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile:&nbsp;(781)
250-0115</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Howard Benjamin</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>With a copy to (but shall not constitute notice to the Purchaser):</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Northern Ave.</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boston, MA 02111</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facsimile: (617) 801-8626</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attention: Arthur McGivern, Esq.; Jason Breen, Esq.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Entire Agreement. </B>This Agreement, including the Ancillary Documents
to be executed by the parties pursuant hereto, contains the entire agreement of the parties hereto and supersedes all prior or contemporaneous agreements and understandings, oral or written, between the parties hereto with respect to the subject
matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Waiver. </B>The terms, conditions, warranties, representations and indemnities
contained in this Agreement, including the Ancillary Documents, may be waived only by a written instrument executed by the Purchaser and the Sellers. Any such waiver shall only be effective in the specific instance and for the specific purpose for
which it was given and shall not be deemed a waiver of any other provision hereof or of the same breach or default upon any recurrence thereof. Except as provided in <U>Section 6.4(c)</U>, no failure on the part of a party hereto to exercise and no
delay in exercising any right hereunder shall operate as a waiver thereof nor shall any single or partial exercise of any right hereunder preclude any other or further exercise thereof or the exercise of any other right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Amendments. </B>No purported amendment, modification or waiver of any provision of this Agreement or any
of the Ancillary Documents shall be effective unless in a writing specifically referring to this Agreement and signed by the applicable parties thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Successors and Assigns. </B>This Agreement shall be binding upon and inure to the benefit of the parties
hereto and their respective heirs, personal representatives, successors and permitted assigns, but except as hereinafter provided in this <U>Section 7.9</U>, nothing in this Agreement is to be construed as an authorization or right of any party to
assign its rights or delegate its duties under this Agreement without the prior written consent of the other parties hereto; provided that no such assignment and/or delegation shall relieve the assignor of any of its duties or obligations hereunder.
Any such assignment by any party hereto without the prior written consent of the other parties hereto shall be null and void <I>ab initio</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.10</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Fees and Expenses. </B>Except as expressly provided for herein, each party hereto shall pay their own
fees and expenses incurred in connection with negotiating and preparing this Agreement and the Ancillary Documents and consummating the transactions contemplated hereby and thereby, including, but not limited to, fees and disbursements of their
respective attorneys, accountants, and financial advisors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.11</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Governing Law and Jurisdiction. </B>This Agreement,
including the Ancillary Documents, shall be construed, governed by and enforced in accordance with the internal laws of the Commonwealth of Massachusetts, without giving effect to the principles of comity or conflicts of laws thereof. The Sellers
and the Purchaser hereby agree and consent that any legal action, suit or Proceeding seeking to enforce any provision of this Agreement, shall be instituted and adjudicated solely and exclusively in any court of general jurisdiction in
Massachusetts, or in the United States District Court having jurisdiction in Massachusetts and the Sellers and the Purchaser hereby agree that venue will be proper in such courts and waive any objection which they may have now or hereafter to the
venue of any such suit, action or Proceeding in such courts, and each hereby irrevocably consents and agrees to the jurisdiction of said courts in any such suit, action or Proceeding. The Sellers and the Purchaser further agree to accept and
acknowledge service of any and all process which may be served in any such suit, action or Proceeding in said courts, and also agree that service of process or notice upon them shall be deemed in every respect effective service of process or notice
upon them, in any suit, action, Proceeding, if given or made (i) according to Applicable Law, or (ii) by a Person over the age of 18 who personally served such notice or service of process on the Sellers or the Purchaser, as the case may be. EACH OF
THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY ACTION OR LIABILITY DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR
THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT.&nbsp;EACH OF THE PARTIES HERETO HEREBY (A)&nbsp;CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY SUCH
ACTION OR LIABILITY, SEEK TO ENFORCE THE FOREGOING WAIVER; AND (B)&nbsp;ACKNOWLEDGES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS
AND CERTIFICATIONS IN THIS <U>SECTION 7.11</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.12</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Counterparts. </B>This Agreement may be executed in
two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same Agreement. A facsimile or emailed .pdf file signature page shall be deemed an original. The counterparts of this
Agreement and all Ancillary Documents may be executed and delivered by facsimile or emailed .pdf file signature by any party to the other parties and the receiving parties may rely on the receipt of such document so executed and delivered by
facsimile or email .pdf file as if the original had been received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.13</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Severability. </B>In the event
that any provision of this Agreement is declared or held by any court of competent jurisdiction to be invalid or unenforceable, such provision shall be severable from, and such invalidity or unenforceability shall not be construed to have any effect
on, the remaining provisions of this Agreement. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Purchaser and the Sellers shall negotiate in good faith to modify this Agreement so as
to effect the original intent of the parties hereto as closely as possible in a mutually acceptable manner in order that the transactions contemplated by this Agreement are consummated as originally contemplated to the greatest extent possible. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.14</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Parties in Interest. </B>Nothing implied in this Agreement
is intended or shall be construed to confer any rights or remedies under or by reason of this Agreement upon any Person other than the Purchaser, the Sellers, and their respective representatives, successors and permitted assigns, except with
respect to the Purchaser Indemnified Parties and the Seller Indemnified Parties as provided for in <U>Article 6</U>.&nbsp;Nothing in this Agreement is intended to relieve or discharge the Liabilities of any third Person to the Purchaser or the
Sellers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.15</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Construction. </B>The parties have participated jointly in the negotiation and drafting of
this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any party by
virtue of the authorship of any of the provisions of this Agreement. The words &#147;including,&#148; &#147;include&#148; or &#147;includes&#148; shall mean including without limitation. The parties intend that each representation, warranty and
covenant contained herein shall have independent significance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.16</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Specific Performanc</B><B>e. </B>The
parties hereto acknowledge and agree that the parties hereto would be irreparably damaged if any of the provisions of this Agreement are not performed in accordance with their specific terms or are otherwise breached and that any non-performance or
breach of this Agreement by any party hereto could not be adequately compensated by monetary damages alone and that the parties hereto would not have any adequate remedy at law. Accordingly, such party shall be entitled to enforce any provision of
this Agreement by a decree of specific performance and to temporary, preliminary and permanent injunctive relief to prevent breaches or threatened breaches of any of the provisions of this Agreement without posting any bond or other undertaking.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>[remainder of page left intentionally blank; signature page follows]</I></B><B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be executed by duly
authorized representatives as of the day, month and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PURCHASER:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>SELLERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>REPLIGEN CORPORATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>NOVASEP PROCESS SAS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tony J. Hunt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Philippe Stoll</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Tony J. Hunt</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:&nbsp;&nbsp;&nbsp;CEO</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Philippe Stoll</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:
President</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Connors</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">John Connors, individually</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>APPENDIX A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes
of this Agreement, the following terms have the meanings specified: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Accounting Referee</I>&#148; means an independent accounting
firm of national reputation mutually acceptable to the Sellers and the Purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Affiliate</I>&#148; when used in reference to
a specified Person, means any Person that, directly or indirectly, through one or more intermediaries, controls, or is controlled by, or is under common control with the specified Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Ancillary Documents</I>&#148; means the documents, instruments and agreements to be executed and delivered by the parties pursuant to
this Agreement; provided however, that Ancillary Documents shall not include the employment agreement and associated employment-related documents for Connors as provided in <U>Section 2.7(d)(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Applicable Laws</I>&#148; means any and all laws (including Environmental Laws), ordinances, constitutions, regulations, statutes,
treaties, rules, codes, licenses, certificates, franchises, permits, requirements and injunctions adopted, enacted, implemented, promulgated, issued, entered or deemed applicable by or under the authority of any Governmental Body having jurisdiction
over a specified Person or any of such Person&#146;s properties or assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Benefit Plan</I>&#148; means any employee benefit
plan within the meaning of Section 3(3) of ERISA whether or not subject to ERISA and all other bonus, stock option, restricted stock, stock purchase, stock appreciation, phantom stock, profit participation, profit-sharing, deferred compensation,
severance, retention, pension, retirement, disability insurance, medical insurance, dental insurance, health insurance, or life insurance, death benefit, incentive, welfare and/or other benefit, compensation and/or retirement plan, policy,
arrangement and/or Contract maintained, sponsored or participated in by TangenX, or to which TangenX could have any Liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Business</I>&#148; means the development, design, commercialization, distribution and manufacturing of flat sheet organic membranes
for biopharmaceutical filtration as conducted by TangenX, in particular tangential flow filtration (TFF) cassettes, and encapsulated TFF devices for laboratory, pilot and production-scale applications in both disposable and reusable formats;
provided, however, that &#147;Business&#148; shall not include the development, design, commercialization, distribution and manufacturing of ceramic or spiral wound membranes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Business Day</I>&#148; means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by
Applicable Law to be closed in the City of Boston, Massachusetts. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Cash and Cash Equivalents</I>&#148; shall mean all unrestricted cash and unrestricted
cash equivalents of TangenX as of immediately prior to the Closing, as determined in accordance with the TangenX Accounting Practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Closing Cash Adjustment</I>&#148; means the amount (the aggregate and/or component parts of which may be negative) equal to the sum
of: (a) the Final Working Capital Amount minus the Estimated Working Capital; (b) the Estimated Indebtedness minus the Final Indebtedness; (c) the Final Cash and Cash Equivalents minus the Estimated Cash and Cash Equivalents; and (d) the Estimated
Transaction Costs minus the Final Transaction Costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Closing Cash Consideration</I>&#148; means the sum of
(a)&nbsp;&#128;37,000,000 (the &#147;<I>Base Price</I>&#148;), plus (b)&nbsp;(i) the Estimated Working Capital minus (ii) the Target Working Capital Amount (which may be negative), plus (c) the Estimated Cash and Cash Equivalents, minus (d) the
Estimated Indebtedness, minus (e) the Estimated Transaction Costs, minus (f)&nbsp;the Escrow Amount; provided, however, that with respect to the Closing Cash Consideration payable to Connors at the Closing, the value of such Closing Cash
Consideration shall be paid in United Stated Dollars, as determined by reference to the relevant exchange rate as published in the Eastern Edition of The Wall Street Journal on the Business Day immediately preceding the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Closing Transaction Expenses</I>&#148; means all fees, costs and expenses incurred by or on behalf of, or paid or to be paid by,
TangenX, TangenX Holding, Novasep, any of their Affiliates, and any of their respective officers and directors in their capacities as such in connection with the structuring, negotiation or consummation of the transactions contemplated by this
Agreement and any other agreement contemplated hereby, including: (a)&nbsp;all such fees, costs and expenses of any brokers, accountants, financial advisors, attorneys, consultants, auditors and other experts; (b)&nbsp;any such fees and expenses
associated with obtaining any consents, or any waivers, consents or approvals of any Person; (c)&nbsp;all brokers&#146;, finders&#146; or similar fees owed by any such Person in connection with the transactions contemplated hereby, including any
process run by or on behalf of TangenX and as provided in <U>Section 3.18</U>; (d)&nbsp;any change of control payments, bonuses, severance, termination or retention obligations or similar amounts payable by or due from TangenX that are triggered
solely by the transactions contemplated hereby; (e) any Transaction Payroll Taxes; and (f) any amounts payable by TangenX in connection with the insurance policies to be obtained in accordance with <U>Section 5.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>COBRA</I>&#148; means the Consolidated Omnibus Budget Reconciliation Act of 1985. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Code</I>&#148; means the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Confidential Information</I>&#148; means TangenX&#146;s ideas, research and development, know-how, technology, formulas,
compositions, manufacturing and production facilities, processes and techniques, technical data, designs, drawings, specifications, customer and supplier lists, pricing and cost information and business and marketing plans and proposals;
TangenX&#146;s computer software (including data and related software program documentation in computer-readable and hard-copy forms); other TangenX Intellectual Property; and proprietary rights of any kind, nature or description of TangenX. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Contract</I>&#148; means any agreement, lease of personal or mixed property, license,
contract, obligation, promise, commitment, arrangement, understanding or undertaking, instrument, document (whether written or oral and whether express or implied) of any type, nature or description that is legally binding<B>.</B> As used herein,
the word &#147;Contract&#148; shall be limited in scope if modified by an adjective specifying the type of contract to which this Agreement or a Section hereof refers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Current Assets</I>&#148; means the current assets of TangenX as determined as of the close of business on the Closing Date without
giving effect to the transactions contemplated by this Agreement and in accordance with the TangenX Accounting Practices; <U>provided</U><I>, </I><U>however</U>, that Current Assets shall not include (a) Cash and Cash Equivalents, or (b) any assets
related to Taxes, whether current or deferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Current Liabilities</I>&#148; means the current liabilities of TangenX as
determined as of the close of business on the Closing Date without giving effect to the transactions contemplated by this Agreement and in accordance with the TangenX Accounting Practices; <U>provided</U><I>, </I><U>however</U>, that Current
Liabilities shall not include (a) any Transaction Costs (other than (x) bonus amounts of the type included in clause (d) of the definition of Transaction Costs and (y) Transaction Payroll Taxes, in each case if expressly set forth on the Estimated
Working Capital Statement solely for purposes of determining the Estimated Working Capital), (b) any Indebtedness of TangenX, or (c) any deferred Tax Liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Data Room&#148;</I>&nbsp;means the electronic documentation site established by SecureDocs, Inc. on behalf of the Sellers and
TangenX. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Encumbrance</I>&#148; means and includes: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;with respect to any personal property, any intangible property or any property other than real
property, any security or other property interest or right, claim, lien, pledge, option, charge, security interest, contingent or conditional sale, or other title claim or retention agreement or lease or use agreement in the nature thereof whether
voluntarily incurred or arising by operation of law, and including any agreement to grant or submit to any of the foregoing in the future; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;with respect to any real property, any mortgage, lien, easement, interest, right-of-way,
condemnation or eminent domain proceeding, encroachment, any building, use or other form of restriction, encumbrance or other claim (including adverse or prescriptive) or right of third parties (including Governmental Bodies), any lease or sublease,
boundary dispute, and agreements with respect to any real property including: purchase, sale, right of first refusal, option, construction, building or property service, maintenance, property management, conditional or contingent sale, use or
occupancy, franchise or concession, whether voluntarily incurred or arising by operation of law, and including any agreement to grant or submit to any of the foregoing in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Environmental Laws</I>&#148; means any and all Applicable Laws (i) regulating the use, treatment, generation, transportation,
storage, control, management, recycling or disposal of any Hazardous Material, including, but not limited to, the Comprehensive Environmental Response, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Compensation and Liability Act (42 U.S.C. &#167; 9601 <U>et</U> <U>seq</U>.), the Resource Conservation and Recovery Act (42 U.S.C. &#167; 6901 <U>et</U> <U>seq</U>.), the Hazardous Materials
Transportation Act (49 U.S.C. &#167; 1801 <U>et</U> <U>seq</U>.), the Federal Water Pollution Control Act (33 U.S.C. &#167; 1251 <U>et</U> <U>seq</U>.), the Clean Water Act (33 U.S.C. &#167; 1251 <U>et</U> <U>seq</U>.), the Clean Air Act (42 U.S.C.
&#167; 7401 <U>et</U> <U>seq</U>.), the Toxic Substances Control Act (15 U.S.C. &#167; 2601 <U>et</U> <U>seq</U>.), and/or (ii) relating to the protection, preservation or conservation of the environment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>ERISA</I>&#148; means the Employee Retirement Income Security Act of 1974, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>ERISA Affiliate</I>&#148; means any entity that would have ever been considered a single employer with TangenX under Section 4001(b)
of ERISA or part of the same &#147;controlled group&#148; as TangenX for purposes of Section 302(d)(3) of ERISA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Escrow
Account</I>&#148; means the escrow account established pursuant to the Escrow Agreement to hold the Escrow Fund. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Escrow
Agent</I>&#148; means Wells Fargo Bank, National Association. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Escrow Agreement</I>&#148; means the Escrow Agreement to be
executed by the Purchaser, Stockholders Representative and the Escrow Agent at the Closing in the form attached hereto as <B><U>Appendix F</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Escrow Amount</I>&#148; means &#128;2,775,000 (i.e., 7.5% of Base Price). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Escrow Fund</I>&#148; means the Escrow Amount together with any interest that may be earned thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Final Cash and Cash Equivalents</I>&#148; means the Cash and Cash Equivalents as shown on the Final Working Capital Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Final Indebtedness</I>&#148; means the Indebtedness of TangenX as of immediately prior to the Closing as shown on the Final Working
Capital Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Final Transaction Costs</I>&#148; means the Transaction Costs as shown on the Final Working Capital
Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Final Working Capital Amount</I>&#148; means the Working Capital Amount as shown on the Final Working Capital
Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Final Working Capital Statement</I>&#148; means the final and binding statement setting forth the Final Cash and Cash
Equivalents, Final Indebtedness, Final Transaction Costs and Final Working Capital Amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>GAAP</I>&#148; means United States
generally accepted accounting principles applied consistently. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Governmental Body</I>&#148; means any: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;nation, state, county, city, town, village, district
or other jurisdiction of any nature; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;federal, state, local, municipal, foreign or other
government; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;governmental or quasi-governmental authority of any nature (including any
governmental agency, branch, board, commission, department, instrumentality, office or other entity, and any court or other tribunal); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;multinational organization or body; and/or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;body exercising, or entitled or purporting to exercise, any administrative, executive, judicial,
legislative, police, regulatory or taxing authority or power of any nature, or any arbitrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Hazardous Materials</I>&#148;
means any and all (i) dangerous, toxic or hazardous pollutants, contaminants, chemicals, wastes, materials or substances listed or identified in, or directly or indirectly regulated by, any Environmental Law, and (ii) any of the following, whether
or not included in the foregoing: polychlorinated biphenyls, asbestos in any form or condition, urea-formaldehyde, petroleum (including crude oil or any fraction thereof), nuclear fuels or materials, chemical wastes, radioactive materials,
explosives and known possible carcinogens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Indebtedness</I>&#148; means, without duplication: (a) any indebtedness for borrowed
money (including the issuance of any debt security); (b) any obligations evidenced by notes, bonds, debentures or similar Contract; (c) any obligations for the deferred purchase price of property, goods or services; (d) any capital lease obligations
categorized as such under GAAP; (e) any obligations in respect of letters of credit and bankers&#146; acceptances; (f) any deferred revenues or prepayments as determined under GAAP; (g) any obligations under any interest rate, currency or similar
hedging agreements; (h) any unpaid Accrued Compensation Amounts as determined under GAAP; (i) all Tax Liabilities of TangenX through the Closing Date; and (j) any guaranty of any such obligations described in clauses (a) through (i) of any Person,
and, in each case, together with all interest, costs, expenses, fees and penalties relating to any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Indemnified
Taxes</I>&#148; means any and all Taxes (i) imposed on TangenX or TangenX Holding for a Pre-Closing Tax Period (including, for the avoidance of doubt, the portion of any Straddle Period ending on or before the Closing Date as determined pursuant to
<U>Section</U> 5.3(b)), and including any Taxes resulting from the sale of Novasep, LLC to Novasep Americas (except to the extent such Taxes have already been an adjustment to the Purchase Price) or the distribution of the stock of TangenX to
TangenX Holding, (ii) of any member of an affiliated, consolidated, combined or unitary group of which TangenX (or any predecessor thereof) or TangenX Holding (or any predecessor thereof) is or was a member on or prior to the Closing Date, including
pursuant to Treasury Regulations Section 1.1502-6 or any analogous or similar state, local or non-U.S. law, (iii) of any Person imposed on each of TangenX and TangenX Holding as a transferee or successor, by Contract, indemnification agreement or
otherwise, or pursuant to any law, which Taxes relate to an event, agreement or transaction occurring on or before the Closing Date, (iv) that are Transaction Payroll Taxes to the extent accrued on or prior to the Closing Date or (v) that are
Transfer Taxes for which the Sellers are responsible pursuant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to <U>Section</U> 5.3(f); <I>provided</I>, that Indemnified Taxes shall not include (x) any Taxes that were included as a Current Liability in the calculation of Working Capital Amount, as
finally determined or (y) any amounts included in the Tax Adjustment Amount that previously reduced the amounts paid to Novasep. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Intellectual Property</I>&#148; means any and all of the following, as they exist throughout the world: (i) patents and patent
applications, together with all reissuances, continuations, continuations in part, divisionals, revisions, extensions and reexaminations thereof (collectively, &#147;<I>Patents</I>&#148;); (ii) rights in registered and unregistered trademarks,
service marks, trade dress, logos, trade names, assumed names and corporate names, packaging design, slogans and Internet domain names, together with all translations, adaptations, derivations and combinations thereof and including all goodwill
associated therewith, and all applications for registration, registrations and renewals in connection therewith (collectively, &#147;<I>Marks</I>&#148;); (iii) published and unpublished copyrightable works, all copyrights and all applications,
registrations and renewals in connection therewith, and all translations, adaptations, derivations, and combinations thereof (collectively, &#147;<I>Copyrights</I>&#148;); (iv) mask works and all applications, registrations and renewals in
connection therewith; (v) rights in know-how, trade secrets and confidential or proprietary information, including inventions, discoveries and invention disclosures (whether or not patented or patentable), research in progress, algorithms, data,
databases, data collections, designs, processes, formulae, schematics, blueprints, flow charts, models, strategies, prototypes, and techniques (collectively, &#147;<I>Trade Secrets</I>&#148;); (vi) any and all other intellectual property rights
and/or proprietary rights; and (vii) copies of tangible embodiments thereof (in whatever form or medium). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Initial Working
Capital Statement</I>&#148; means a statement setting forth the Purchaser&#146;s good faith determination of the calculations covered by the Estimated Working Capital Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Knowledge</I>&#148; means, with respect to an individual who is a natural being, an individual&#146;s actual knowledge of a fact or
other matter after conducting a reasonable investigation. With respect to an entity that is a party to, or a subject of this Agreement, &#147;Knowledge&#148; shall be solely attributed to the Knowledge of each officer or director. For purposes of
&#147;<I>Knowledge of the Sellers</I>&#148; or similar term used herein, the Knowledge of any Seller shall result in all Sellers having Knowledge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Liability</I>&#148; or &#147;<I>Liabilities</I>&#148; means any and all debts, liabilities, claims, losses, damages, deficiencies,
interest, penalties, costs, expenses and/or obligations of any type, nature or description (whether known or unknown, asserted or unasserted, secured or unsecured, absolute or contingent, accrued or unaccrued, liquidated or unliquidated and whether
due or to become due). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Losses</I>&#148; means any and all losses, costs, expenses (including without limitation, reasonable
attorneys&#146; fees and disbursements of counsel), Liabilities, damages, interest, Taxes, fines, penalties, charges, assessments, judgments, settlements, claims, causes of action, and other obligations of any nature whatsoever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Objection Deadline Date</I>&#148; means the date forty-five (45) days after delivery by the Purchaser to the Sellers of the Initial
Working Capital Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Ordinary Course of Business</I>&#148; means an action taken by a Person only if </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;such action is consistent with the past practices of such Person and is taken in the ordinary course
of the normal day-to-day operations of such Person; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;such action is not required to be
authorized by the board of directors of such Person (or by any Person or group of Persons constituting a governing body of a Person exercising similar authority). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Permits</I>&#148; means all right, title and interest in and to any permits, licenses, filings, authorizations, approvals, or other
indicia of authority (and any pending applications for approval or renewal of a Permit), to own, construct, operate, sell, inventory, disburse or maintain any asset or conduct any business as issued by any Governmental Body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Person</I>&#148; means any individual, corporation (including any non-profit corporation), general, limited, or limited liability
partnership, limited liability company, joint venture, estate, trust, association, organization, or other entity or Governmental Body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Pre-Closing Tax Period</I>&#148; means any taxable period that ends on or before the Closing Date, and the portion of any Straddle
Period ending on, and including, the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Proceeding</I>&#148; means any suit, claim, litigation, arbitration, hearing,
audit, investigation, order, or other action (whether civil, criminal, administrative or investigative) noticed, commenced, brought, conducted, or heard by or before, or otherwise involving, any Governmental Body or arbitrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Pro Rata Share</I>&#148; means with respect to Novasep 79.71% and with respect to Connors 20.29% as calculated and listed on
<B><U>Appendix C</U></B>; except that, with respect to any claims subject to Section 6.2(b), Novasep&#146;s Pro Rata Share shall be 100%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Related Persons</I>&#148; means, with respect to a particular individual, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;each other member of such individual&#146;s Family (as hereafter defined); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp; any Affiliate of one or more members of such individual&#146;s Family. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to a specified Person other than an individual: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;any Affiliate of such specified Person; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;each Person that serves as a director, officer, manager, general partner, executor or trustee of such
specified Person (or in a similar capacity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this definition, the &#147;<I>Family</I>&#148; of an individual includes (i)
such individual, (ii) the individual&#146;s spouse, (iii) any lineal ancestor or lineal descendant of the individual, or (iv) a trust for the benefit of any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Representative</I>&#148;&nbsp;means, with respect to any Person, any and all directors,
officers, employees, consultants, financial advisors, counsel, accountants and other agents of such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Rights</I>&#148;
means any and all outstanding subscriptions, warrants, options, convertible debt, preemptive rights or other arrangements or commitments obligating or which may obligate (with or without notice or passage of time or both) TangenX or TangenX Holding
to issue or dispose of any of its respective (as opposed to third party) securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Straddle Period</I>&#148; means any taxable
period that includes (but does not end on) the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>TangenX Accounting Practices</I>&#148; means the historical
accounting practices of TangenX as of immediately prior to the Closing, applied on a consistent basis, taking into account the exclusions set forth on <B><U>Appendix H</U></B> attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>TangenX Intellectual Property</I>&#148; means all Intellectual Property owned or purported to be owned by TangenX, used or held for
use by TangenX in the Business or that was developed by or for TangenX.&nbsp;&#147;<I>TangenX Intellectual Property</I>&#148; includes, without limitation, the Products, TangenX Patents, TangenX Marks, and TangenX Trade Secrets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Target Working Capital</I>&#148; means $1,300,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Tax</I>&#148; or &#147;<I>Taxes</I>&#148; means any and all U.S. federal, state, local or municipal, or foreign taxes, including (but
not limited to) net income, gross income, gross revenue, gross receipts, net receipts, ad valorem, franchise, profits, transfer, sales, use, social security, employment, unemployment, disability, license, withholding, payroll, privilege, excise,
value-added, severance, stamp, occupation, property, unclaimed property, environmental, customs, duties, real estate and/or other taxes, assessments, levies, fees or charges of any kind whatsoever imposed by any Governmental Body, together with any
interest or penalty relating thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Tax Returns</I>&#148; means any return, declaration, report, claim for refund or
information return or statement relating to Taxes, including, without limitation, any schedule or attachment thereto, any amendment thereof and any estimated report or statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Threatened</I>&#148; means a claim, Proceeding, dispute, action, or other matter for which any demand or statement has been received
(in writing or orally) by TangenX, a Seller or one of their respective Affiliates that would lead a reasonably prudent Person to conclude that such a claim, Proceeding, dispute, action, or other matter may be asserted, commenced, taken or otherwise
pursued in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Transaction Costs</I>&#148; means all fees, costs and expenses incurred by or on behalf of, or paid or to
be paid by, TangenX, TangenX Holding, and any of their respective officers and directors in their capacities as such in connection with the structuring, negotiation or consummation of the transactions contemplated by this Agreement and any other
agreement contemplated hereby, including: (e)&nbsp;all such fees, costs and expenses of any brokers, accountants, financial advisors, attorneys, consultants, auditors and other experts; (f)&nbsp;any such fees and expenses associated with obtaining
any consents, or any waivers, consents or approvals </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of any Person; (g)&nbsp;all brokers&#146;, finders&#146; or similar fees owed by any such Person in connection with the transactions contemplated hereby, including any process run by or on behalf
of TangenX and as provided in <U>Section 3.18</U>; (h)&nbsp;any change of control payments, bonuses, severance, termination or retention obligations or similar amounts payable by or due from TangenX that are triggered solely by the transactions
contemplated hereby (solely to the extent not expressly included as a Current Liability in the calculation of Estimated Working Capital); (e) any Transaction Payroll Taxes (solely to the extent not expressly included as a Current Liability in the
calculation of Estimated Working Capital); and (f) any amounts payable by TangenX in connection with the insurance policies to be obtained in accordance with <U>Section 5.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Transaction Payroll Taxes</I>&#148; means the employer portion of any payroll or employment Taxes payable by TangenX attributable to
any cash outs, bonuses or other compensatory payments made in connection with the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Treasury Regulations</I>&#148; means the final, temporary and proposed regulations promulgated by the United States Treasury
Department under the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Unresolved Objections</I>&#148; means the objections set forth on the Sellers&#146; Notice of
Disagreement delivered to the Purchaser pursuant to <U>Section 2.5</U> that remain unresolved pursuant to <U>Section 2.5(d)(iii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Working Capital Amount</I>&#148; means the Current Assets less the Current Liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d312959dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">


<IMG SRC="g312959g1215033933377.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen Corporation</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">41 Seyon
Street</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Building #1, Suite 100</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham,&nbsp;Massachusetts&nbsp;02453</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Repligen Acquires TangenX Technology Corporation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Adds innovative <FONT STYLE="white-space:nowrap">single-use</FONT> Sius&#153; TFF technology to downstream bioprocessing portfolio </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALTHAM, MA &#150; December</B><B></B><B>&nbsp;15, 2016 &#150; </B>Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing
technology leadership, today announced that it has acquired TangenX Technology Corporation (&#147;TangenX&#148;) of Shrewsbury, MA, maker of the innovative <FONT STYLE="white-space:nowrap">single-use</FONT> Sius&#153; line of tangential flow
filtration (&#147;TFF&#148;) cassettes and hardware used in downstream biopharmaceutical manufacturing processes. Sius TFF is used in the filtration of biological drugs, complementing Repligen&#146;s
OPUS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> line of <FONT STYLE="white-space:nowrap">Pre-Packed</FONT> Chromatography Columns used in downstream purification. <FONT STYLE="white-space:nowrap">Single-use</FONT> Sius TFF cassettes
are designed to deliver superior performance to traditional (reusable) TFF cassettes in a cost-competitive format that provides user-ready convenience and flexibility. The Sius portfolio also strengthens the Company&#146;s existing capability in
filtration, where its XCell&#153; ATF products (both stainless steel and <FONT STYLE="white-space:nowrap">single-use)</FONT> are used for perfusion and cell culture intensification in upstream manufacturing processes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the acquisition, TangenX was controlled by Novasep Holding SAS of Lyon, France. The acquisition by Repligen was completed through an all cash
transaction of EUR 37.0&nbsp;million (USD 39.0 million). Repligen expects sales of TangenX products to achieve double-digit growth and contribute <FONT STYLE="white-space:nowrap">$7.0-$7.5&nbsp;million</FONT> in revenue for the year 2017. This
acquisition is expected to be accretive on both a GAAP EPS and adjusted EPS basis in 2017. Goodwin Procter LLP served as legal counsel to Repligen in the deal, and EC Mergers and Acquisitions, a EuroConsult company, provided financial advisory
services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tony J. Hunt, President and Chief Executive Officer of Repligen said, &#147;This strategic acquisition strengthens our position as a leader in <FONT
STYLE="white-space:nowrap">single-use</FONT> bioprocessing technologies and extends our reach into downstream processes, where disposables are increasingly being adopted by biopharmaceutical manufacturers for the convenience, flexibility and cost
advantages that they offer. Our companies share a common culture of innovation, and we look forward to working with the entire TangenX team to drive further growth of this platform and develop next generation products for our customers.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Connors, President of TangenX said, &#147;Our commitment to delivering high value and flexible TFF solutions to the bioprocessing industry is closely
aligned with Repligen&#146;s focus on technological innovation as a path to market success. We have seen strong demand for Sius TFF over the last few years, and look forward to combining forces with Repligen to drive further adoption of Sius and our
joint portfolio of products.&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About TFF and Sius&#153; <FONT STYLE="white-space:nowrap">single-use</FONT> cassettes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tangential flow filtration (TFF) is a rapid and efficient method for separation and purification of biomolecules that is widely used in laboratory, process
development and process scale applications in biopharmaceutical manufacturing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sius&#153; is an innovative
<FONT STYLE="white-space:nowrap">single-use</FONT> TFF line of cassettes and hardware for <FONT STYLE="white-space:nowrap">lab-scale</FONT> through process-scale biopharmaceutical manufacturing. <FONT STYLE="white-space:nowrap">Single-use</FONT>
Sius TFF cassettes with enclosed flat sheet membranes are designed to offer a lower cost alternative to reusable TFF products. Each disposable cassette is delivered <FONT STYLE="white-space:nowrap">pre-sanitized,</FONT> integrity tested and ready to
be equilibrated and used for tangential flow diafiltration and ultrafiltration processing. TangenX studies demonstrate that utilizing Sius TFF in downstream processing will typically reduce filter costs by 80%, labor by 50% and buffer usage by 75%,
eliminating <FONT STYLE="white-space:nowrap">non-value</FONT> added steps of cleaning and flushing. Sius TFF cassettes are interchangeable with filter hardware from multiple manufacturers, simplifying customer trial and adoption of Sius products.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Repligen Corporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen Corporation
(NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to manufacture biologic drugs. Our bioprocessing products are sold to major life sciences companies,
biopharmaceutical development companies and contract manufacturing organizations worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A resins that are used to separate and purify monoclonal
antibody-based therapeutics. In upstream processes, our XCell&#153; ATF systems and growth factors are used to accelerate and increase productivity during the cell culture stage of biologic drug manufacturing. In downstream processes, we developed
and market our innovative line of OPUS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> chromatography columns that we deliver <FONT STYLE="white-space:nowrap">pre-packed</FONT> with our customers&#146; choice of resin for their bench-scale
through clinical production-scale purification needs. With the acquisition of TangenX, we also manufacture <FONT STYLE="white-space:nowrap">single-use</FONT> Sius&#153; TFF cassettes and hardware, used in downstream protein concentration and
filtration processes. Repligen&#146;s corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA, Shrewsbury, MA, Lund, Sweden and Weingarten, Germany. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following constitutes a &#147;Safe Harbor&#148; statement under the Private Securities Litigation Reform Act of 1995: This press release contains
forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements
in this press release which are not strictly historical statements, constitute forward-looking statements, including, without limitation, express or implied statements or guidance regarding future financial performance of TangenX product revenue,
customer adoption of the SIUS product line, future financial performance of Repligen, including the accretive nature of the TangenX acquisition, expected synergies following the acquisition of TangenX and other statements identified by words like
&#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;seek,&#148; &#147;anticipate,&#148; or &#147;could&#148; and similar expressions. Such forward-looking statements are subject to a number of risks
and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: our ability to integrate TangenX&#146;s business and personnel and to achieve expected synergies;
our ability to maintain or expand TangenX&#146;s historical sales; our ability to accurately forecast the acquisition, related restructuring costs and allocation of the purchase price, goodwill and other intangibles acquisition related and other
asset adjustments; our ability to develop and commercialize products and the market acceptance of our products; reduced demand for <FONT STYLE="white-space:nowrap">single-use</FONT> or disposable bioprocessing products that adversely impacts our
future revenues, cash flows, results of operations and financial condition; our volatile stock price; and other risks detailed in Repligen&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> on file with the
Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These
forward looking statements reflect management&#146;s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except
as required by law. </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sondra S. Newman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(781)
<FONT STYLE="white-space:nowrap">419-1881</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">snewman@repligen.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g312959g1215033933377.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g312959g1215033933377.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !2 2,# 2(  A$! Q$!_\0
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MUX38^%?$.HW:VT&CWNYI/++/ RJC=]S$8&/>O?/B;J4ND>$1J,+%9+>[@D!
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MD W-Z!>]7*SY-&LY;U+IO.WI()0@F8)O'\17."?PK0H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
